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I. Background 
 
A larger proportion of cancer patients survives their initial diagnosis and remains tumour-free for 
longer periods than has been observed in previous decades (Janssen-Heijnen, et al., 2010). Hand 
in hand with this favourable development goes also an increased interest in ‘life after cancer’. In 
other words, while survival has been a topic of major attention for many years, survivorship 
issues dealing with other aspects of life after cancer beyond survival have gained increasing 
interest in the oncological community during the last two decades. 
1 Cancer Survival and sources of information 
1.1 Cancer statistics worldwide 
 
Data on incidence and mortality after cancer worldwide can be accessed by public databases 
(Parkin, et al., 1997). For Europe, relevant data on cancer survival have been published in 
EUROCARE-4 (Verdecchia, et al., 2007). This report comprises survival data for patients 
diagnosed with cancer in 2000–02, collected from 47 of the European cancer registries 
participating in the EUROCARE-4 study. Mean five-year relative survival was estimated for the 
European mean and for five European regions, and findings were compared with those from the 
US SEER registry (SEE). Survival for patients diagnosed in this time period was generally 
highest for those in northern European countries and lowest for those in eastern European 
countries. The pronounced differences in survival are only partly due to cancer treatment and 
access to diagnostic and treatment facilities but can also be attributed to other factors such as 
prevention, screening programs and socio-economic status. 
Concerning cancer care in the Nordic countries, the NORDCAN database and program 
(Engholm, et al., 2010) includes detailed information and results on cancer incidence, mortality 
and prevalence in each of the Nordic countries (Denmark, Faroe Island, Finland, Iceland, 
Norway and Sweden) over five decades. The NORDCAN database has lately been supplemented 
with predictions of cancer incidence and mortality. Age-specific mortality and incidence rates 
are similar in all the Nordic countries (Engholm, et al., 2010). 
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1.2 Cancer statistics in Norway 
 
In 2008, 26,121 new cases of cancer were recorded in Norway (Cancer of Norway, 2008), of 
which 14,000 occurred among men and 12,121 among women. As of December 2008, over 
190,000 persons were alive and previously diagnosed with cancer in Norway (4.0% of the whole 
population of 4.8 million) and 115.030 (2.4%) were alive at least five years after their cancer 
diagnosis.  
Today, about two thirds of patients with first-time cancer diagnosis can expect to survive five 
years, with or without tumour activity (Figure 1 and Figure 2, both from Cancer in Norway 
2007).  
This positive development of increased cancer survival in general and in particular for selected 
diagnoses (Armitage, 2010; Kuruvilla, 2009; Horwich, et al., 2006) is related to improved cancer 
treatment. Further, malignancies tend to be earlier and more correctly diagnosed than some 
decades ago due improved diagnostic possibilities. Establishment of screening programs - such 
as mammography screening (Kalager, et al., 2010) for breast cancer and PSA testing for prostate 
cancer (Andriole, et al., 2009; Schroder, et al., 2009) aims to detect cancers at a very early stage 
and may contribute to an increased public awareness of the risk and clinical signs of cancer. The 
increased survival rates have contributed to an increased activity in the field of cancer 
survivorship, among other aspects dealing with long-term morbidity, cure rates and non-medical 
factors with impact on survival.  
 
Figure 1: Trends in incidence, mortality and 5-year relative survival by gender (1965-2008) 
Males: blue line: incidence; light blue line: mortality; green line: survival  
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Females: dark red line: incidence; light red line: mortality; brown line: survival. 
 
 
Figure 2: 5-year relative survival by cancer and sex, sorted in descending order of male survival. 
1.3 Population- and hospital-based registries 
 
Each individual living in Norway is assigned a unique 11 digit identification number at birth 
which enables merging of data and linkage of information from different registries. The data 
required for the projects of this thesis have been retrieved information from the registries 
described below. 
Cancer Registry of Norway (CRN) 
 
Each patients newly diagnosed with a neoplasms or certain precancerous lesions has to be 
reported to the Cancer Registry of Norway (CRN) following a directive from the Ministry of 
Health and Social Affairs in 1951, further strengthened by the Health Registry Act in 2002 that 
included statutory regulations and the requirement that relevant institutions report new cases to 
the Registry. A recent evaluation suggests that multiple source reporting and effective trace-back 
has meant that the Registry has retained a high level of overall completeness for many years 
(Larsen, et al., 2009). In terms of validity, the Registry’s effective use of reports from pathology 
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laboratories, clinical records and death certificates has been shown to provide reasonable and 
comparable accuracy. Only a small fraction of cancer registrations was solely obtained from 
death certificate sources (DCO) (Larsen, et al., 2009). A review of registrations from 2001 to 
2005 showed that three-quarters of the main cancer sites had a DCO proportion of less than 1%. 
However, for certain sites, including pancreatic and liver cancer, the percentages were higher, 
ranging from 3 to 4%.  
Cancer type, date of diagnosis, extent of the disease (EOD), at diagnosis and initial treatment in 
broad terms are recorded at the CRN.  Unfortunately, specific information on the type of 
chemotherapy, radiotherapy doses or target fields is not available, nor date of eventual 
recurrence or treatment of this. In general, extent of disease of solid tumours is classified as 
localized, with regional spread, with distant spread, or of unknown extent.  
Statistics Norway (SSB)  
 
Statistic Norway (SSB) provides statistics on the Norwegian population. For this thesis, data on 
vital status, emigration, eventual date of death and education level were retrieved. 
The patient registry of the NRH 
 
The Norwegian Radium Hospital (NRH) is a tertiary referral hospital for malignancies requiring 
radiotherapy and/or intensive chemotherapy. Up to 1980, patients with Hodgkin’s lymphoma 
(HL), testicular (TC), cervical or ovarian cancer from the whole country (except for Bergen 
region) were referred to the NRH for primary treatment. After 1980, along with the 
establishment of four other Norwegian oncological academic units in the country, referral was 
mostly restricted to patients living in the Southern Norway. An electronic patient registry 
contains demographic and limited medical information for patients treated after 1970.   
Surveillance Epidemiology and End Results (SEER) registry 
 
The SEER program of the National Cancer Institute (NCI) is an authoritative source of 
information on cancer incidence and survival in the United States (US). Data collection on 
cancer cases has begun on January 1, 1973. Currently it collects and publishes cancer incidence 
and survival data from population-based registries covering approximately 28% of the whole US 
population. SEER coverage includes 25% of white Americans, 26% of African Americans, 41% 
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of Hispanics, 43% of American Indians and Alaska Natives, 54% of Asians, and 71% of 
Hawaiian/Pacific Islanders.  
The SEER Program registries routinely collect data on patient demographics (birth year, age at 
diagnosis, gender, and marital status), primary tumour site, tumour morphology and EOD, initial 
surgery and/or radiotherapy. The SEER Program is the only comprehensive source of 
population-based information in the US that includes stage of cancer at the time of diagnosis and 
patient survival data. The mortality data that are reported to SEER are provided by the National 
Centre for Health Statistics. 
Medical Birth Registry of Norway (MBRN) 
 
MBRN was established in 1967, and collects data on pregnancies lasting of at least 16 weeks 
(from 1999 all gestations with a duration of at least 12 weeks), which are compulsorily reported 
by all doctors and midwives. Regarding data of interest for this thesis, the MBRN provides 
information on demographic data of the parents, their reproductive history, mortality and 
possible emigration date. In addition, this registry provides information regarding the pregnancy, 
such as date of the last menstruation and gestational duration and whether the pregnancy was 
initiated by assisted reproductive technologies (ART). Date of birth of the newborn is registered, 
together with measurements such as weight and length and vital status. Adoptions are not 
registered. 
 
1.4. Survival estimates derived from large registries 
 
Cancer registries usually base their survival analyses on death certificates whose validity 
concerning causes of death may be questioned. Estimates from survival analyses with the cause 
of death as the end-point can therefore be debated.  However, several studies from Scandinavia 
and recently also related to the SEER registry were able to document correctness of the cause of 
death in at least 80% of the death certificates (Johansson, et al., 2000; Johansson, et al., 2002; 
Lund, et al., 2010).   
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Overall survival 
 
When estimating overall survival, death of all causes is considered as an endpoint of survival 
analyses. The different causes of death are not distinguished from one another and patients are 
censored only at the end of follow up or when lost to follow up. 
Cause specific survival 
 
Cause-specific survival can be calculated when reliable information on a cause of death is 
available (Pandey, 2002). It is calculated in the same manner as overall survival but only death 
caused by an event of interest (meaning a pre-specified cancer) is considered as an event while 
other causes of death are treated as censored observations. Estimation of cause-specific survival 
can be obtained using the Kaplan-Meier method.  
However, it may be difficult to pinpoint a particular cause of death, especially for cancer patients 
with several severe co-morbidities, and to classify the cause of death as due to cancer or other 
causes. 
Relative survival 
 
In order to circumvent the above-mentioned problems regarding reliability of causes of death, 
Cancer Registries most often report relative survival where the duration of survival in cancer 
patients is related to that of the general population. 
Relative survival was defined by Bergson-Gage (Bergson-Gage, 1950) as the ratio of the 
observed survival in a group of cancer patients and the expected survival of the general 
population. Cancer registries most often report relative survival, most frequently as 5- or 10-year 
survival. Stratifications are performed by age, sex and calendar year and when possible, other 
factors as race and socioeconomic status. 
The main advantage of this method is the fact that information on cause of death is not required. 
The problems with the inaccuracy or non-existence of death certificates can therefore be avoided 
and all deaths occurring during the study period can be included in the analysis. The availability 
of a comparable group from the general population is crucial for estimating the expected survival 
correctly. Hence population-based mortality tables have to be available. 
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Conditional relative survival 
 
Conditional relative survival is defined as the probability of a cancer patient to survive an 
additional number of years given he/she has survived a given number of years since diagnosis. 
This estimate is more informative compared to the conventional relative survival. The longer a 
cancer patient survives after his/her diagnosis the more informative is such an estimate compared 
to the conventional relative survival. For example when a 5-year conditional relative survival 
reaches 100% fifteen years after the cancer diagnosis, it indicates that after this time there is little 
or no excess mortality among this patient group and their mortality is the same as observed in the 
general cancer-free population (Cancer of Norway, 2008). 
Proportion cured and median survival of fatal cases 
 
The favourable trend in cancer survival has warranted the development of novel statistical tools 
to monitor the effectiveness of early-detection strategies and the quality of clinical care and 
cancer management, including procedures to estimate the proportion of cured patients alongside 
the median survival of fatal cases using so-called cure models (de Angelis, et al., 1999; 
Heinavaara, et al., 2006; Verdecchia, et al., 2002). Possible scenarios in terms of trends in 
median survival of fatal cases and survival of those considered cured are depicted in Figure 3 
(after (Verdecchia, et al., 2007)). According to Lambert et al (Lambert, 2007), scenario 
a. (a) represents a general improvement, an increased proportion of patients is cured and 
those patients we are unable to cure have a longer median survival time than those 
treated earlier.  
b. Scenario (b) suggests selective improvement: previously incurable patients are now 
cured, i.e. so the proportion of cured patients is higher but the median survival time of 
fatal cases is reduced.  
c. Scenario (c) might occur following improved palliative care of fatal cases but, 
alternatively, could arise if new diagnostic techniques were brought into the health care 
system, so that patients are diagnosed earlier without affecting the time of death (lead 
time bias).  
d. Finally, scenario (d) might occur when a specific diagnostic procedure is introduced and 
one is able to diagnosed patients who would have most likely died of other causes before 
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their cancer would give symptoms. These patients have no excess risk relative to the 
general population. 
 
 
Figure 3: Scenarios for trends in proportion cured and median survival of the uncured. 
 
The inherent differences between the concepts of clinical versus statistical cure need to be 
understood. Statistical cure is applicable to observations examined at the group level, and is 
distinct from medical cure of the individual, as commonly determined in a clinical setting on the 
basis of lack of specific symptoms of the patients, achieved, for example, when there is no longer 
any evidence of residual malignant cells. (Lambert, 2007). The models, when applied to 
population-based cancer survival data, serve to provide estimates of the proportion of 
statistically-cured individuals, that is, a group of cancer patients who, after a certain time period, 
are observed to have little or no excess mortality relative to the general population.  
Such models have been applied to aid clinical interpretation of survival trends for specific cancer 
sites in one or more population. A recent EUROCARE study presented estimates of the cured 
proportion for a limited number of cancer forms (lung, stomach, colon, rectum and breast) for a 
subset of European cancer patients diagnosed from 1988 to 1999 (Francisci, et al., 2009). 
Lambert et al have reported the long-term survival trends among colorectal cancer patients in 
Finland, in terms of the proportion cured and median survival of fatal cases (Lambert, 2007), 
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while trends in the proportion of childhood cancer patients with leukaemia have been studied in 
British children diagnosed between 1971 and 2000 (Shah, et al., 2008). 
 
1.5 Prognostic and predictive factors 
 
Identification and assessment of prognostic and predictive factors is one of the major tasks in 
clinical cancer research. The goal of prognostic studies is to determine survival or in more 
general terms to attempt to predict the course of the disease for groups of patients defined by the 
values of prognostic factors and to rank the relative importance of the various prognostic factors 
(Crowley, et al., 2006). One has to distinguish between prognostic and so-called predictive 
factors; the latter term is used when one investigates whether a specific treatment works in a 
particular subgroup of patients. In contrast to studies designed to evaluate predictive factors for 
which statistical methods and principals are well-developed and generally accepted, this is not 
the case for studies that aim to evaluate prognostic factors. 
Although there has been some positive development in this field in the recent years, most of the 
studies investigating prognostic factors are based on historical data and the sample sizes are often 
too small to provide reliable results. Statistical aspects of prognostic factor studies have been 
addressed in textbooks on survival analysis (Marubini, et al., 1995; Parmar, et al., 1995), and 
recently in a monograph on prognostic factors in cancer (Gospodarowicz, et al., 2001). These 
authors interpreted the three major criteria for prognostic factors as established by The American 
Joint Committee on Cancer (AJCC) (Burke, et al., 1993). The factors have to be significant, 
independent, and clinically relevant: “significant” means that the prognostic factor rarely occurs 
by chance; “independent” implies that such factor retains its prognostic value even in presence of 
other prognostic factors; and “clinically important” means that such a factor has an influence on 
patients’ management and possible outcome.  
 
1.6 Demographic and socio-economic variables 
 
During recent years there has been an increasing interest in studying the significance of health 
disparity for survival of cancer patients. Patient’s age, race and socio-economic status have been 
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investigated as prognostic factors together with inequalities of the healthcare system (Murphy, et 
al., 2010; Boyle, 2003). 
In this thesis the term “socio-economic status” (SES) covers civil status and educational level of 
the individual person or a group of individuals, whereas factors such as age, race and place of 
residence are viewed as demographic factors. Data on financial income and assets are other 
important socio-economic factors, but were not available for our analyses. However, the 
educational level related to the place of residence (county) was viewed as a surrogate factor for 
the socio-economic situation of the individuals as also done by Hofmann et al (Hoffman, et al., 
2008) in an analysis of TC patients. 
Age 
 
In general: for most patients with adult-onset cancer, increasing age represents an independent 
prognostic factor for cancer-specific survival, even when initial extent of the disease is 
considered (Gorey, 2009; Rowe, 2010; Ramirez, et al., 1999; Group, 2000). Most often this 
relates to reduced treatment-intensity, based on the experience of increased risk of treatment-
related complications in the older population. However, in the clinical settings there is a growing 
understanding that the cut-off point between “young” and “old” patients should not be based on 
chronological, but on biological age, taking into account the patient’s performance status and 
eventual co-morbidities. 
Testicular cancer (TC) patients: Though (TC) is a malignancy of young men, males up to the 
age of 90 years can be diagnosed with TC (Andreassen, et al., 2010). Clinicians have 
experienced that advancing age increases the risk of unfavorable outcome both after bleomycin-
containing chemotherapy and after other chemotherapy regiments (Simpson, et al., 1998) 
(O'Sulivan, et al., 2003) and RPLND complications (Capitanio, et al., 2009) in metastatic 
patients. Further, improved renal function and reduced bone marrow reserves may lead to 
suboptimal dose modifications in older patients (Inci, et al., 2007).  
 
As of 2008 no large survival analyses have compared survival between older and younger TC 
patients, which is the main reason why paper II was initiated. At that time one was aware of the 
excellent prognosis of TC patients and that one would require access to large registry-based 
databases to detect potential differences in survival between patients’ groups. 
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Civil status 
 
In general: the prognostic role of civil status for cancer survival is uncertain. Some studies have 
shown that single cancer patients in univariate analysis display decreased survival rates 
compared to married ones. For example, single individuals do more rarely participate in 
screening programs and sometimes lack sufficient social support during their treatment period 
(Quaglia, et al., 2005; Boffetta, et al., 1993). On the other hand Ramirez et al (Ramirez, et al., 
1999) could not identify any relationship between breast cancer survival and civil status.  
TC patients: the prognostic role of civil status has not yet been assessed in population-based 
analysis in this group of patients.  
Race 
 
In general: race has been shown to be an important prognostic factor for many cancer sites 
though the reasons for this observation are not clearly understood. Sometimes an underlying 
biological difference between Caucasians and non-Caucasians is discussed as the cause for 
survival differences. The prognostic significance of race is often reduced when socio-economic 
factors, life style, extent of the disease and treatment are in multivariate analysis considered as 
co-variates together with race. Most studies have compared Afro-Africans with Caucasians 
living in the US (McKenzie, et al., 2009; Williams, et al., 2009; Alexander, et al., 2007). 
TC patients:  in a hospital-based series of TC patients Bridges et al in 1998 observed that 5-year 
cancer specific survival among African Americans was decreased by 17% lower (Bridges, et al., 
1998). In 2004 Biggs et al (Biggs, et al., 2004) confirmed these findings based on SEER series 
including 16 086 patients treated from 1973 to 1999. Based on SEER (1973-2000) Nguyen and 
Ellison (2005) (Nguyen, et al., 2005) demonstrated lower unadjusted survival rates for Asian-
American males with TC than for Caucasian ones, the difference disappearing after adjustment 
for extent of the disease and histology. Gajendran et al. reported similar results for African-
American TC patients, indicating that African-American men’s survival inferiority was related to 
higher extent of the disease at diagnosis (Gajendran, et al., 2005).  
Place of residence, calendar year of treatment and public health care service 
 
In general: in cancer patients, the place of living and calendar year of diagnosis are highly 
related to the selection of treatment by the health care service. 
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TC patients: for these cancer patients this relationship has been clearly shown for men living in 
Eastern Germany (Boyle, 2003) and in the EUROCARE study from 2007 (Sant, et al., 2007). 
Additionally, the results were principally confirmed by Aareleid et al in 2010 (Aareleid, et al., 
2010) , in a study of TC patients from Estonia. For Norwegian testicular cancer patients 
significant survival improvement has been observed for patients diagnosed early in the 1980ies. 
The positive development is explained by the advent of cisplatin-based chemotherapy as the 
initial treatment of patients with metastatic TC from the beginning of the 80ies (Figure 4, after 
Cancer in Norway 2008). 
 
 
Figure 4: TC patients diagnosed 1965-2008 in Norway. Dark blue: incidence; light blue: 
mortality, green: survival 
Socio-economic status 
 
The association between socio-economic status (SES) and cancer survival has been examined in 
several epidemiologic studies within a variety of study designs (Kravdal, 2000; Rosso, et al., 
1997; Cella, et al., 1991). A number of these are ecologic studies using geographical-area based 
measures based on the geographical area as SES indicators (comparing richer with poorer areas). 
Others are hospital-based or record linkage cohort studies with individual information on 
socioeconomic status measured by socioeconomic group, income or level of education. 
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Regardless of study design, a number of studies have found improved cancer survival by 
increasing SES, both overall and for specific anatomic sites, especially for cancers of relatively 
good prognosis such as female breast, corpus uteri, and bladder cancer. A few studies found no 
association between SES and overall cancer survival. In general, the observed differences in 
survival by SES seem to be lower in ecologic studies than in studies with individual assessment 
of SES. Tumour characteristics as EOD have been claimed to contribute to the SES variation in 
cancer survival, whereas the limited information on lifestyle factors in previous studies leaves 
the role of patient characteristics unclear. 
Further, one has discussed a possible inter-relationship between SES and race. For patients living 
in Ontario (Canada), Mackillop et al  had shown in 1997 that the economic situation of the area 
of a testicular cancer patient’s residence was positively related to their five years survival 
(diagnosis in 1982 – 1991; (Mackillop, et al., 1997). This report however did not analyze 
histology and extent of the disease. 
A study on Norwegian women from 2009 found an overall negative socioeconomic gradient in 
cancer survival when SES was measured as years of education or gross household income. In 
addition, smoking status prior to diagnosis was an important predictive factor for socioeconomic 
variation in survival. (Braaten, et al., 2009). Although the wide gap in life expectancy between 
the affluent and the relatively poor citizens in modern societies is well-documented, such 
differences can be detected also in supposedly equalitarian Nordic countries. In a study based on 
a Norwegian sample aged over 40 years and observed from 1960-1991 the excess all-cause 
mortality among cancer patients compared with similar persons without a cancer diagnosis was 
significantly related to education, occupation, and income (Kravdal, 2000). Excess mortality 
was, on the whole, about 15% lower for men or women who had completed a post-secondary 
education than for those with only compulsory schooling, taking into account age, period and 
registered differences in tumour characteristics and stage at the time of diagnosis. 
In TC patients: Power et al (Power, et al., 2001) found a significant negative effect of socio-
economic deprivation on relative 5-year survival of TC patients living in Wales UK, the 
differences decreased comparing men diagnosed from 1991–1995 with those diagnosed from 
1986–1990. No separation was done between seminoma and non-seminoma, and EOD was not 
considered.  
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2 Cancer survivorship 
2.1 Cancer patients versus cancer survivors 
 
The term ‘cancer survivor’ was introduced in 1985 by Mullan who outlined three stages of 
survival: ‘acute survival’—usually taking place in the first year after treatment; ‘extended 
survival’—the few years after active treatment; and ‘permanent survival’—long-term survival, 
when the risk of recurrence is significantly reduced, but there may still be risks of late 
consequences of treatment, including secondary malignancy (Mullan, 1985). 
Among health professionals, people with a cancer history, and the general public, views differ as 
to when a person with cancer becomes a survivor. The Institute of Medicine in the USA (htt) 
prefers to consider a person to be a survivor from the moment of diagnosis. Others consider a 
person with cancer to be a survivor if he or she lives 5 years beyond diagnosis.  
The term ‘cancer survivor’ has thus been defined differently by different groups. In this 
summary of the thesis we will not distinguish between “cancer survivors” and “cancer patients” 
but we will prefer the latter term.  
2.2 Long- term treatment-related morbidity in cancer patients  
 
Any treatment-related morbidity persisting or developing for at least one year after cancer 
treatment will in this thesis be described as ‘Long-term’. Post-cancer long-term morbidity may 
be life threatening e.g. cardiovascular disease (Aleman, et al., 2007; Haugnes, et al., 2010) or 
second cancer (Hudgson, et al., 2007; Travis, et al., 2005), or can reduce the patient’s quality of 
life (QoL) and general well-being by inducing side effects such as  neurotoxicity (Brydøy, et al., 
2009), mental distress  or  involuntarily-reduced reproduction (Schover, 2009; Foster, et al., 
2009), the latter being one of the issues of the present thesis. 
However, the unbiased assessment of morbidity in cancer patients and its causes represent major 
problems due to the frequent lack of suitable populations-based registries, which record non-fatal 
medical events in identifiable individuals and allow comparisons with general population data. In 
the Nordic countries and in some other European countries (Sousa, et al., 2006) there has been a 
growing interest in using existing databases such as Discharge registries, Prescription registries 
(Furu, et al., 2009) and established disease specific registries, for example the Norwegian 
Arthroplasty register, as sources of information on morbidity after cancer. 
 22 
2.3 Young cancer patients 
 
Cancer is generally a disease of individuals beyond the age of 50 years. In this phase of life most 
patients have had the number of children they want, and post-diagnosis reproduction is a minor 
concern when diagnosed with cancer. Further, beyond the age of 50 most women are no longer 
able to conceive. On the other hand, changes in the society with an increasing proportion of 
divorces and second and third marriages have led to an increasing number of men who become 
fathers after the age of 50 years. According to the MBRN, 0.42% of all men fathering a child 
during 1980 to 1987 were aged ≥50 years. This figure increased to 1.1% for the period 2000-
2007 (Vernar Sundvor, personal communication). 
About 6 % of patients diagnosed between 2004 and 2008 were aged 15–44 years and TC and BC 
diagnoses were the most frequent ones among respectively males and females (Table 1). These 
patients are defined here as adult-onset cancer patients (excluding childhood cancer survivors). 
The majority of such patients can expect to be survivors for at least 5 years as illustrated in 
Figure 5. For these adolescent and young adult cancer patients post-diagnosis reproduction and 
the chance of future parenthood represent an important concern.  
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Figure 5: 5-year relative survival for patients (males/females) aged 15-44 in Norway. 
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Table 1: New cancer cases aged 15–44 and diagnosed 2004-2008 
(Data available online http://www.kreftregisteret.no/no/Registrene/Kreftstatistikk)/ 
 
Males New cases 
diagnosed  
2004-2008 
Females New cases 
diagnosed  
2004-2008 
All diagnosed patients 
15-44 years old at diagnosis 
749 All diagnosed patients 1053 
Selected most common diagnoses 
Testicular cancer 223 (30%) Breast cancer 292 (28%) 
Brain tumours (CNS) 81 (11%) Malignant Melanoma 132 (13%) 
Malignant melanoma 74 (10%) Cervical cancer 119 (11%) 
Malignant lymphoma  
(Hodgkin’s and Non-
Hodgkin’s) 
64 (9%) Brain tumours 82 (8%) 
Leukemia 28 (4%) Malignant lymphoma 
(Hodgkin’s and Non-Hodgkin’s) 
46 (4%) 
  Thyroid cancer 43 (4%) 
  Ovarian cancer 35 (3%) 
  Leukemia 24 (2%) 
Others 279 (37%) Others 280 (27%) 
 
2.4 Testicular cancer  
 
Testicular cancer patients are in the focus of this thesis as they represent a group of patients with 
a very good prognosis and the majority is diagnosed at a young age. Thus post-diagnosis 
reproduction is therefore of particular importance.  
Incidence: Testicular germ-cell cancer represents about 96% of all malignant testicular tumours 
and is the most frequent malignancy in men between the 20–40 years. The incidence is 
increasing in the Western countries, with Norway and Denmark displaying the highest 
incidences worldwide (10/100 000) (Chia, et al., 2010). Among Caucasians Americans 15–49 
years old, the incidence was 6.3/100 000 in 2004, 0.8/100 000 among black African-Americans 
and was 1.7/100 000 among other non-whites (Holmes, et al., 2008).  In spite of the overall 
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excellent prognosis, small though important differences may be associated with prognostic 
factors which might be identifiable in large registry based samples. 
Histology/staging: Seminoma is distinguished from non-seminoma, the latter with several 
subtypes of minor therapeutic importance. According to the CRN ( 1953-2007) approximately 55 
% of all new TC patients present with a seminoma, and 45% with a non-seminoma (Andreassen, 
et al., 2010). The median age of patients with seminoma was 36 years (range: 1-91) in 
Andreassen et al’s study, as opposed to median 30 years  in men with non-seminoma (range: 1-
85 years). Following recommendations from the Royal Marsden Hospital, UK, the clinical stages 
(CSs) are defined as follows (Peckham, 1988): 
 
I Testicular tumour only  
IM 
Elevated levels of AFP and/or HCG without 
visible metastases 
II 
   A: < 2cm 
   B: 2-5cm 
   C: >5cm 
Infra-diafragmal lymphadenopathy 
 
III 
   A: < 2cm 
   B: 2-5cm 
   C: >5cm 
Supra-diaphragmal  lymphadenopathy 
 
IV 
Extra-lymphatic metastases (lung, liver, bone, 
etc.) 
 
With background in changes in the registration routines in CRN and SEER during several 
decades, in this thesis localized non-metastatic testicular cancer (stage I) is distinguished from all 
metastatic stages (stage II-IV). A majority (75-80%) of the seminoma patients have a localized 
disease as compared to 50-60% of men with non-seminoma (Horwich, et al., 2006).  
At the end of the 1970ies the relevance of serum tumour markers (alpha foetoprotein [AFP], 
human chorio- gonadatropin [HCG]) for diagnosis, treatment and follow-up of testicular cancer 
patients was established. An international consensus group was then able to define a staging 
classification with improved prognostic significance (Group, 1997)  
Treatment: All patients undergo unilateral orchiectomy to provide the histological specimen.  
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After orchiectomy European and US patients with localized seminoma have traditionally 
received adjuvant abdominal pelvic radiotherapy (Zagars, 1996; Fosså, et al., 1988) although 
field size and target dose have gradually been reduced (Fosså, et al., 1999; Jones, et al., 2005) 
(Table 2). This tradition has been maintained in the United States until recently in the majority of 
patients, whereas new treatment modalities have been introduced in Europe and Canada with 
surveillance (Warde, et al., 2002) or adjuvant chemotherapy with carboplatin (Oliver, et al., 
2005). In patients with localized non-seminoma, retroperitoneal lymph node dissection (RPLND) 
was used in the US as a staging procedure and definite treatment as non-seminoma which is less 
radio-sensitive than seminoma. (Fraley, et al., 1979a; Fraley, et al., 1979b; Steele, et al., 1999). 
Surveillance of stage I patients with non-seminoma has become a frequently used alternative 
treatment during the last 15 years both in Europe and North America (Hotte, et al., 2010; 
Schmoll, et al., 2009; Tandstad, et al., 2009). 
Up to the late 1980ies the treatment of metastatic TC has consisted of available chemotherapy: 
cyclophosphamide, methotrexate, actinomycin D, vinblastine, bleomycin, adriamycin and 
oncovin ( (Klepp, et al., 1977; Katz, et al., 1978). In 1977 Einhorn and Donohue demonstrated 
the excellent survival response rates in metastatic patients treated with cisplatin combinations 
(Einhorn, et al., 1977). Since then, cisplatin-based chemotherapy has become the cornerstone for 
patients with metastatic testicular cancer often combined with post-chemotherapy retroperitoneal 
lymph node dissection (RPLND) (Horwich, et al., 2006; Heidenreich, et al., 2009; Oldenburg, et 
al., 2009; Janssen-Heijnen, et al., 2010; Oliver, et al., 2005). 
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Table 2: Strategies of post-orchiectomy treatment of testicular germ cell tumours (TGCT) in 
Norway. Similar routines are applied in the USA though with more use of retroperitoneal surgery 
in non-seminoma) 
Extent of the 
disease 
1953-1979 
 
1980-2007 
 
Localized Seminoma Non-seminoma Seminoma Non-seminoma 
RAD 1(30-40 Gy) RAD 1 (40-50 Gy) RAD 1 (20-30 Gy) 
Surveillance or 
adjuvant 
chemotherapy 
(2005+) 
Retroperitoneal 
surgery or 
surveillance 
(1990+) or 
adjuvant low-dose 
chemotherapy 
Metastatic Chemotherapy2 
RAD3 
Chemotherapy2 
RAD3 
Chemotherapy4    +/-
RAD3/surgery 
Chemotherapy4 
+/- surgery 
1Abdominal radiotherapy.  
2Alkylating drugs, anthracyclines, vinca alkaloids, metothrexate 
3Involved field radiotherapy. 
4Cisplatin-based chemotherapy  
 
Survival: Today the mean 5-year relative survival rate is 97.3% in Europe, and 95.4% for 
patients from SEER (13 registries) (Verdecchia, et al., 2009). Of note, the overwhelming 
majority of patients are rendered tumour-free within the first 2-3 years. Recurrences after two 
years, i.e. late relapses, are rare (Oldenburg, et al., 2006). Testicular cancer survivors who had 
survived for five years had a similar survival rates as the age-matched general population 
(Janssen-Heijnen, et al., 2010).   
2.5 Human reproduction 
2.5.1 Physiology of reproduction 
Males: 
 
Reproduction in males requires the post-pubertal production of mature sperm cells regulated by 
testosterone and hormones from the pituitary gland. From the testis the sperm cells have to be 
transported through the male genital tract, a process ending with antegrad ejaculation during 
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erection. Disruption of any of these transport mechanisms has obviously negative consequences 
for reproduction.  
Females:  
 
At birth the ovaries contain 1–2 million immature oocytes (primordial follicles), which are 
progressively lost from 400 000 at puberty to about 1000 at the age of 50 (menopause). During 
the first half of a menstrual cycle the immature oocytes mature, the process ending with 
ovulation. During the second half of the menstrual cycle, hormonal influences (estrogens, 
progesterone) prepare the uterus for nidation of the fertilized ovum. Any intervention that 
reduces the number of immature oocytes, for example due to ovarian surgery, radiotherapy or 
systemic chemotherapy increases the risk of early menopause, in spite of transient post-diagnosis 
recovery of the menstrual cycle. Furthermore, any cancer surgery or radiotherapy which disturbs 
transportation, nidation and maturing of the fertilized ovum reduces the chance of post-diagnosis 
reproduction.  
2.5.2 Cancer therapy and post-diagnosis reproduction 
Definitions: 
 
Post-diagnosis reproduction in cancer patients is one of the main topics of the present thesis. The 
term post-diagnosis reproduction is used to describe whether or not a patient diagnosed with 
adult-onset cancer has become a father or mother of at least one child after his/her cancer 
diagnosis and with an estimated date of conception after the date of diagnosis. The expression 
“gonadal function” describes the ability of the testis and ovaries to produce sex-hormones and 
mature eggs or sperm cells. The term “fertility” addresses a person’s ability to become a parent 
thus requiring the normal function of ovaries or testes and other genital organs.  
Cancer treatment may transiently or permanently reduce or abolish spermatogenesis, reduce the 
number of oocytes with the consequence of early menopause, or it may lead to hormonal 
disbalance and/or disturb the normal function of the genital organs required for physiological 
transport of the ovum and sperm cells.  
In addition to any somatic aspects of reproduction, the diagnosis and treatment of a life- 
threatening malignancy may cause psychosocial and socioeconomic problems, the latter 
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theoretically associated with reduced reproduction even in somatically healthy individuals (Joffe, 
et al., 1995; Dehlendorf, et al., 2010). 
This thesis does not aim to discern these possible causes of impaired reproduction in cancer 
patients. Further, post-diagnosis sub-/infertility in cancer patients may be an inherent component 
of malignancy as is the case in a few females with ovarian germ cell cancer (androgen 
insensitivity syndrome) (Lukusa, et al., 1991). Pre-treatment infertility has also been claimed to 
be a component of the testicular dysgenesis syndrome (Wohlfahrt-Veje, et al., 2009) which has 
been linked to the etiology of testicular cancer. However, the correlation between pre-treatment 
sub-/infertility and TC and the existence of a testicular dysgenesis syndrome and decreased pre-
diagnosis fertility in TC patients have recently been challenged (Akre, et al., 2009; Kim, et al., 
2010). 
Surgery  
 
Males: Except for the obvious negative effect of surgical removal of genital organs on post-
diagnosis reproduction, the transport of sperm cells is threatened by any pelvic or retroperitoneal 
operation which carries the risk of resection of nerves. This is for example the case after 
retroperitoneal lymph node dissection (RPLND), frequently performed in patients with TC, who 
experience post-operative “dry ejaculation” (Brydøy, et al., 2009; Grigor, et al., 1993) 
Females: Removal of the genital organs (uterus, ovaries, and vagina) is often required in case of 
invasive genital cancer and obviously eliminates the possibility of post-diagnosis motherhood.  
Radiotherapy 
 
Males: The spermatogenesis is highly affected by irradiation. Fractionated testicular radiation at 
doses between 0.2 – 0.7 Gy, as commonly applied during abdomino-pelvine radiotherapy of 
patients with Hodgkin’s lymphoma (HL) and TC, results in transient reduction in sperm cell 
concentrations. Testicular radiation doses of more than two Gy usually lead to permanent 
infertility. (Jacobsen, et al., 1997).  
Females: Depending on the age of the patient, radiotherapy causes cell death of the immature 
oocytes and radiation doses of about 4 Gy lead to oocyte reduction by 50 %. At the woman’s age 
of 30 the effective sterilizing radiation dose is 14.3 Gy (Wallace, et al., 2005). 
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Chemotherapy 
 
Depending of the choice of the cytostatic agents, their combination and cumulative doses and the 
age of the patient, there is a risk of post-chemotherapy infertility (Lee, et al., 2006) 
Males: The most gonado-toxic cytostatic drugs are procarbazine and alkylating agents (such as 
cyclophosphamide), Prior to 1987, procarbacin was used in patients with Hodgkins lymphoma, 
as a part of their standard chemotherapy (MOPP: metocloretamin, vincristine, procarbacin, 
prednisolone) (De Vita, et al., 1987). The ABVD combination (adriamycin, bleomycin, 
vinblastine, and dacarbazine) was developed during the 1980ies and is less toxic than the MOPP 
regime (Bonadonna, et al., 1982).Recovery of spermatogenesis can be expected in the majority 
of patients after treatment with ABVD (Viviani, et al., 1991).The standard treatment of non-
Hodgkins lymphoma (CHOP: cyclophosphamide, adriamycin, vincristine, prednisolone) 
(Juliusson, et al., 1989). is in general less gonadotoxic than the MOPP chemotherapy for HL 
patients (Kiserud, et al., 2009). Before 1970, chemotherapy for TC mostly consisted of high 
cumulative doses of cyclophosphamide, eventually combined with methotrexate. In the 1970ies, 
bleomycin, vinblastine or vincristine, actinomyacin D and adriamycin were used; the 
gonadotoxic effect of these agents and their combination mostly depend on their cumulative 
doses (Klepp, et al., 1977).  
Cisplatin-based chemotherapy, used as the initial treatment in testicular cancer patients in 
Norway after 1980, results in temporary azoospermia in most men with the recovery in about 
50–80 % of them  (Lampe, et al., 1997; Brydøy, et al., 2005),depending on the patients age and 
cumulative dose.  
Females: The MOPP regimen previously used in patients with HL leads to premature 
menopause and infertility in most females with improvement of the reproduction rates after 
introduction of the ABVD regimen. Adjuvant chemotherapy in treatment of breast cancer causes 
early menopause with high dependency on the woman’s age (Zervoudis, et al., 2010). Anti-
estrogen treatment for 2–5 years used in the treatment of breast cancer has by itself no direct 
gonadotoxic effect, but delays the prospect of a pregnancy for several years (Liebens, et al., 
2008).  
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2.5.3 Fertility saving tasks 
 
As it is not possible to predict the recovery of gonadal function and the ability of post-treatment 
reproduction in the individual patient, fertility-saving tasks should be offered before and during 
cancer therapy in any patients who considers post-treatment parenthood.  
 
Males: In Norway, cryopreservation of semen has been offered to male cancer patients since 
1980. Semen cryopreservation should always be offered, though only less than 10 % of 
Norwegian cancer patients who have stored pre-treatment semen sample ever use their deep-
frozen semen  (Kiserud, et al., 2007; Magelssen, et al., 2005). Nerve-sparing RPLND techniques 
have been developed during the 1980ies in patients with TC (resulting in perseveration of 
antegrade ejaculation in 90 % of the operated patients (Foster, et al., 1993). In case of disturbed 
transport of sperm cells, microsurgical epidermal aspiration of testicular sperm extraction can be 
considered. During pelvic radiotherapy testicular shielding should always be performed to reduce 
scattered testicular irradiation (Jacobsen, et al., 1997).  
Females: Embryo cryopreservation has been offered in Norway since early in the 1980s. Today 
pre-treatment cryopreservation of ovarian tissue and of unfertilized eggs is performed in 
Norway, but is still an experimental task (Oktem, et al., 2009; Hulvat, et al., 2009). Fertility-
saving surgical procedures have been introduced for early stages of gynecological cancer, such 
as conisation and trachelectomy in women with early cervical cancer. Fertility-saving surgical 
procedures have also been developed for early ovarian cancer  
In women post-diagnosis  fertility and gonadal function have mostly been analyzed for 
patients with Hodgkin’s lymphoma, ovarian germ cell cancer, early cervical cancer and 
choriocarcinoma. 
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2.5.4 Fertility and reproduction in patients with selected cancer sites 
Males 
 
Testicular cancer 
The chemotherapy applied in TC patients before the cisplatin era was often followed by 
permanent azospermia in survivors, whereas abdominal radiotherapy had a less deleterious effect 
(Fosså, et al., 1986). Bilateral radical retroperitoneal lymph node dissection (RPLND), as 
frequently viewed necessary in non-seminoma patients diagnosed in USA  before the 80s, always 
lead to “dry ejaculation“ and permanent infertility. Approximately two years after modern 
Cisplatin-based standard chemotherapy spermatogenesis has recovered in at least 80% of 
testicular cancer survivors (TCSs) with sperm counts sufficient for initiation of a pregnancy 
(Huddart, et al., 2005). These observed sperm counts are comparable to the 80% 15-year 
paternity rate in TCSs with antegrade ejaculation and post-treatment fatherhood (Brydøy, et al., 
2005). 
Compared to the situation before 1979 and taking into account the fertility-saving treatments of 
TC introduced in Norway in the 1980s (Tandstad, et al., 2009; Jacobsen, et al., 1999), TC 
survivors’ improved post-diagnosis reproduction rates should be evident in patients diagnosed 
from the end of the 1980s onwards.  
Hodgkin’s lymphoma 
The mean age at diagnosis for HL in males is 30 years, and about 50% of the patients have at 
least one child before the start of anti-cancer treatment (Fossa, et al., 2004; Viviani, et al., 1985). 
The MOPP combination, the standard treatment therapy up to approximately 1987, was followed 
by permanent infertility in more than 90% of male HL- survivors. After introduction of the 
ABVD treatment as standard treatment and omission of alkylating agent-based therapies, serum 
hormone analyses indicate that spermatogenesis recovers in approximately 80% of male HL 
patients (van der Kaaij, et al., 2007). BEACOPP chemotherapy (Diehl, et al., 2006), for high risk 
HL patients (approximately 10 patients per year in Norway) was introduced in Norway in 2000 
and leads to persistent infertility in 90% of the patients (Sieniawski, et al., 2008). 
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Females 
 
Hodgkin’s lymphoma 
The introduction of ABVD chemotherapy and avoidance of pelvic radiotherapy have increased 
the chances of post-treatment motherhood in approximately 80% of female HLSs who attempted 
pregnancy (Kiserud, et al., 2007; Hodgson, et al., 2007). However even woman who regain 
menstrual cycles after treatment are at risk for developing premature ovarian failure POF after 
15–20 years of observation (Haukvik, et al., 2006). Patients diagnosed after the age of 30 years 
are at particular high risk of POF is for patients diagnosed after the age of 30 years. Eight 
courses of BEACOPP chemotherapy is followed by permanent infertility in almost all females 
(Behringer, et al., 2005).  
Breast cancer 
Approximately 10% of breast cancer diagnoses occur in woman younger than 45 years. For most 
of them, the question of future post-diagnosis motherhood is not relevant because they have 
completed their families. On the other hand, many women in industrialized countries now delay 
motherhood to an age of 30 to 35 years. Because of adjuvant cytostatic treatment and several 
years of hormone therapy, the 10-year cumulative rate of post-diagnosis pregnancies is low, 
although childbirth has been reported after adjuvant chemotherapy, even when combined with 
tamoxifen. 
Gynecologic cancer 
Approximately 40% of women who have cervical cancer and 9% of those who have ovarian 
cancer are younger than 45 years of age. Because their treatment often consists of dissections of 
the reproductive organs or high-dose pelvic radiotherapy post-treatment reproduction rates are 
very low. Some improvement has to be expected  after the introduction of fertility-saving surgery 
(Sjøborg, et al., 2007; Boss, et al., 2005). Cisplatin-based chemotherapy of ovarian germ cell 
cancer (Gershenson, et al., 2007) and treatment with Methotrexate for choriocarcinoma (Goto, et 
al., 2004) are followed by recovery of the ovarian function in almost all patients. Overview of 
the cytotoxic drugs and their effect on gonadotoxicity is listed in Table 3 (modified after Lee and 
Schover (Lee, et al., 2006). 
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Table 3: Cytotoxic drugs and gonadotoxicity 
Single drug 
 
Combination drugs 
Low risk 
 vincristine 
 vinblastine 
 dactinomycin (actinomycin D) 
 bleomycin 
 methotrexate 
 mercaptopurine 
 
Low risk 
 ABOD (adriamycin, bleomycin, 
vincristine, dacarbazine) 
 ABVD (adriamycin, bleomycin, 
vinblastine, dacarbazine) 
 
 
. 
Medium risk 
 cisplatin 
 carboplatin 
 doxorubicin 
 etoposid 
 
Medium risk 
 BEP (cisplatin, etoposid, bleomycin) 
 CHOP (cyclophosphamide, adriamycin, 
vincristine, prednison) 
 CVB (cisplatin, vinblastin, bleomycin) 
 BEP (bleomycin, etoposid, cisplatin) 
 
High risk 
 
 cyclophosphamide 
 mechlorethamine 
 ifosfamide  
 busulfan 
 chlorambucil 
 procarbazine 
 
High risk 
 MOPP(mechlorethamine, vincristine, 
procarbazine, prednisolon) 
 CAOS (cyclophosphamid, adriamycin, 
vincristine, actinomycin D) 
 BEACOPP (cyclophosphamid, 
adriamycin, vincristine, etoposide, 
procarbazine, bleomicin, prednisone) 
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II. The present project 
Proportion of cure 
 
In spite of the experience of increasing survival rates in cancer patients, not all 5-year survivors 
are “cured”. Both patients and health administrators are, however, interested in what proportion 
of patients with a malignant diagnosis can be cured—meaning that their survival is similar to that 
of the general population. Bearing these questions in mind, in 2007 the Cancer Registry of 
Norway (CRN) decided to analyze the data using a published statistical model that estimates 
both the proportion of cured patients and median survival time of fatal cases. Despite being 
available in the literature for a long time, cure models have seldom been applied and 
systematically tested across all major cancer sites. 
Age and socio-economic status as prognostic factors for men with testicular cancer  
 
Published literature on TC did not consider age, race and SES combined with medical data in 
one multivariate analysis, despite the fact that clinical experience indicated the prognostic 
significance of these factors. Therefore we decided to assess the relation between age and SES 
and survival also taking into account demographic variables, histology and EOD using data from 
a large database.  
Post-diagnosis reproduction 
 
As of 2007 only a few large studies had reported post-diagnosis reproduction rates in patients 
with adult-onset cancer. Further, in most cases the published observations on post-diagnosis 
fertility and reproduction reflected mono-institutional experience among patients with selected 
malignancies, and usually without a control group from the general population.  
In 2006 Fosså et al published a preliminary report on post-diagnosis reproduction among patients 
treated at the NRH by linkage of the clinical database of the NRH (established in 1971) with the 
CRN and the MBRN. This study demonstrated that male cancer patients had lower post-
treatment reproduction rates than observed in the general population (Magelsen, et al., 2006). 
The highest proportions of patients with at least one pregnancy after their cancer diagnosis were 
observed among patients with malignant lymphoma, testicular cancer, malignant melanoma and 
choriocarcinoma (respectively 18 %, 20 %, 16 % and 50 %), whereas the comparable figures for 
 36 
breast and cervical cancer were low (respectively 2 % and 1 %). Increasing age and pre-
treatment parenthood decreased the reproduction rates. This preliminary publication on patients 
treated at the NRH did not relate post-diagnosis reproduction to treatment and its changes and 
reported only results of univariate analyses. Having these raw data available, we wanted to 
analyse them using more advanced analytical and statistical methods. Subsequently, we became 
aware of the selection bias related to the patients treated at the NRH.  
We thus wanted to further explore post-diagnosis reproduction in an unselected group of patients 
identifiable in CRN. New detailed analyses should be restricted to post-diagnosis reproduction 
rates in men and women, for whom the complete history of reproduction was known.  
 
 
 
Ethical concerns 
 
The estimation of proportion of statistically cured patients was regarded as a part of the routine 
tasks to be performed at the CRN (Paper I). According to the Norwegian laws valid in 2006, the 
Data Inspectorate and the Ethical Committee approved the linkage between the registries used to 
identify patients used in Paper III and Paper IV, whereas no ethical concerns were raised for the 
use of the publically accessible SEER database (Paper II). 
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III. Aims of this thesis 
The principal objective of this thesis is to illustrate whether and under what conditions 
clinically valuable information retrieved from large population-based and hospital–based 
registries can be used to investigate prognostic factors that impact on survival and post-
diagnosis reproduction rates of cancer patients. 
Our hypothesis is that it would be possible to identify patients with a favourable outcome and 
those with an impaired outcome (in terms of survival and post-diagnosis fertility) based on 
data accessible in large population-based and hospital-based registries. We aimed specifically 
at answering the following questions: 
 
1. Can a proportion of statistically cured patients be estimated for a wide range of cancer 
diagnoses? Can such estimates of statistical cure and median survival time of fatal cases be 
meaningfully interpreted in the context of improved cancer care over time?  
Our hypothesis is that the cure model can be used to estimate a proportion of cured cancer 
patients together with a median survival time of fatal cases and to calculate changes in these 
estimates over time. In addition, we expected to be able to show that survival times of fatal 
cases have increased in line with anticipated improvement in palliative care. 
 
2. What is the impact of increased age and low socio-economic status in a population-based 
sample of testicular cancer patients?  In a population-based series of testicular patients, we 
expected high age and low socio-economic status to be associated with increased TC 
specific mortality. 
 
3. What is the rate of post-diagnosis reproduction in adult-onset cancer patients compared to 
the general population and what factors influence this rate? We hypothesized that the post-
diagnosis reproduction rates in cancer patients would be significantly lower than in 
comparable individuals from the general population. We expected several factors such as 
gender, type and extent of cancer, pre-diagnosis parity and calendar period of diagnosis to 
influence the rates of reproduction. In addition, we hypothesized that the impact of the 
above mentioned factors would differ among the different cancer sites.  
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IV. Patients, methods and results 
1 Paper I: Proportion Cured Models Applied to 23 Cancer Sites in 
Norway 
1.1 Identification of study population 
 
National incidence and follow-up data on Norwegian cancer patients was extracted from the 
Cancer Registry of Norway. The 23 most-frequently recorded cancers for the diagnostic period 
1963–2007 were selected for the analysis and follow-up on matching vital status was obtained 
from the Deaths Registry at Statistics Norway. Following some necessary eliminations, 627 346 
cases were included in the analyses, 97.7% of the total.  
. 
1.2 Statistical methods 
 
There is a methodological difference between being clinically and statistically cured. The 
concept of statistical cure is applicable at a group level and is distinct from medical cure at an 
individual level. Medical curability is commonly determined on the basis of lack of specific 
symptoms of the individual, and it is achieved when all cancerous cells in the body have been 
persistently eradicated (Lambert, 2007). Medical cure cannot usually be studied using population 
based cancer registry data. However, it may be possible to calculate a proportion of statistically 
cured cancer survivors who as a group, exhibit the same mortality as observed in the general 
population. 
The cure proportion was estimated using the mixture cure proportion model. This model, when 
applied to population-based cancer survival data, serves to provide estimates of the proportion of 
statistically-cured individuals, that is, a group of cancer patients who, after a certain time period, 
are observed to have little or no excess mortality relative to the general population. In addition, 
cure model provides an estimate of a median survival time of fatal cases (cancer patients who are 
bound to die of their cancer). 
Temporal trends between 1963–2002 in the proportion of cured patients, and the median survival 
of fatal cases, were estimated applying the complete approach as suggested by (Brenner, et al., 
2004), whereby all diagnosed cases over the period regardless of the length of their follow-up 
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were used in the estimations. The main focus here was on estimating changes in trends for 
patients diagnosed at different five-year time periods; hence period of diagnosis was modeled as 
a categorical variable with the 5-year periods as the categories.  
The changes in proportion cured and median survival of uncured cases between the first period 
(1963–1967) and the last period (1998–2002) were quantified as the absolute difference between 
the estimates of both cure proportion and median survival with the corresponding 95% 
confidence intervals.   
The most up-to-date estimates of the proportion of cured patients and the median survival of fatal 
cases were modeled using period approach with a 3-year observation window (2005–2007) and a 
15-year follow-up, thus accruing sufficient case numbers to ensure the estimates were reasonably 
up-to-date while retaining an acceptable degree of precision. Using this method the follow-up 
was set to 15 years but there were no constraints on the model concerning the time at which a 
statistical cure will have to be reached.  
1.3 Results 
 
The cure models fitted well for cancers of the mouth and pharynx, esophagus, stomach, colon, 
rectum, liver, gallbladder, pancreas, lung and trachea, ovary, kidney, bladder, CNS, non-Hodgkin 
lymphoma and leukaemia. The up-to-date proportion of cured patients was highest for those with 
bladder cancer and CNS tumours (67% and 64%, respectively). It was not possible to fit the cure 
proportion for eight of the 23 selected neoplasms (breast, prostate, cervical, endometrial, 
testicular, thyroid, Hodgkin lymphoma and melanoma of the skin). In addition, changes in 
proportion cured patients and in median survival of fatal cases between the diagnostic period 
1963–1967 and the period 1998–2002 were calculated.  
The largest changes in the cured proportion were observed for patients with bladder cancer (73.4 
% for males and 68.9% for females) and CNS tumours (52.1% for males and 71.3 for females). 
Median survival time for patients with uncured colon cancer increased from 0.42 to 0.61 years, 
for rectal cancer from 0.56 to 0.73 years and for ovarian cancer from 0.73 to 1.36 years between 
the above defined diagnostic periods.   
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2 Paper II: Adverse prognostic factors for testicular cancer-specific 
survival: a population-based study of 27,948 U.S. patients 
2.1 Identification of study population 
 
Men were included in this study if they were registered in the SEER database 
(http://seer.gov/data; Nov 2008 Submission) with a histologically confirmed invasive germ cell 
TC as a first primary malignancy at age 15 years or older between January 1, 1978 and 
December 31, 2006. Based on age at TC diagnosis, patients were categorized into two groups: 
“younger”: age: 15-39 years (corresponding to peak incidence rates for TC) and “older” age: 40+ 
years. Extent of the disease (EOD) was dichotomized into “localized” and “metastatic” disease. 
Three calendar year periods after 1977 were identified: Period 1: 1978–1987; Period 2: 1988–
1997; and Period 3: 1998–2006.   
In addition, socio-economic, demographic and medical information were retrieved from the 
SEER database. Data concerning the use of initial post-orchiectomy radiotherapy were available 
for all patients and since 1998, also information regarding RPLND. No data were available with 
regard to type and dose of chemotherapy nor date of treatment or relapse. Vital status for each 
patient was determined through December 31, 2006, including date and cause of death. Each 
individual patient was assigned an educational class (EDUC class) by county of residence at TC 
diagnosis according to results of the U.S. Census (1980, 1990 or 2000), whichever was closest to 
the patient’s year of TC diagnosis. The EDUC class was viewed to represent the level of SES 
(Hoffman, paper II, nr.10 ref). In this study, EDUC was categorized based on tertiles of the 
distribution of “county educational class”.  
2.2 Statistical methods 
 
The primary outcome was TC-specific mortality. The cumulative incidence functions and 
disease-specific hazard ratios were estimated using competing risks survival analysis techniques 
(Fine, et al., 1999). TC specific mortality was the main event of interest and death of other 
causes as the competing event.  
Follow-up was defined as time from diagnosis to date of death or study cutoff date (December 
31, 2006), whichever occurred first. In addition, for selected analyses, follow-up was right-
censored at ten years after TC diagnosis since (1) the proportional hazards assumption is more 
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tenable for limited time periods and (2) most TC-specific deaths occurred within the first decade 
after diagnosis. 10-year TC-specific mortality rates were estimated together with 95% confidence 
intervals. 
Multivariable competing risk Cox models were fitted separately for seminoma and for non-
seminoma patients. The proportional hazards assumption was tested using the scaled Schoenfeld 
residuals and with visual inspection of the log minus log plots. Predictors included age at 
diagnosis (<40 years vs 40+ years), race (non-Hispanic whites vs others), and marital status 
(married vs unmarried), EOD (localized vs metastatic), calendar year of diagnosis (<1988 vs 
1988+). Socio-economic status was coded as an ordinal variable, whereby 1 (highest SES) was 
the reference, and 3 was the lowest.  Seminoma patients were also categorized based on whether 
or not they were treated with radiotherapy. A separate Cox regression analysis restricted to the 
latest calendar year period (1998–2006) was analyzed with the same variables (except for 
radiotherapy and year of TC diagnosis) to explore the influence of RPLND on TC-specific 
mortality in non-seminoma patients. Patients missing any of the above predictors were excluded 
from the multivariable analyses.  
2.3. Results 
 
The study cohort comprised 27,948 TC patients (57% seminoma, 43% non-seminoma); 74% of 
them were categorized as “younger” (age <40) and 26% as “older” (age 40+). Ninety-three 
percent of the patients were white. Compared with younger patients, diagnostic age 40+ was 
associated with increased TC-specific mortality (seminoma: HR=2·00, 95%CI: [1.54 to 2.61], 
non-seminoma: HR=2·09, 95%CI: [1.72 to 2.55]), and most evident in metastatic disease 
(HR=8.62, 95%CI: [6.38 to 11.65], and HR=6.35, 95%CI: [5.23 to 7.70], respectively). 
Unmarried men had 2-to 3-fold excess mortality compared to married men, respectively. Among 
non-seminoma patients, the mortality was significantly higher with low levels of SES and for 
non-white race. For seminoma, the effect of race and SES was not significant. Diagnosis after 
1987 resulted in reduced mortality compared to earlier calendar years (HR=0·58, 95%CI: [0.42 
to 0.80], and HR=0·74, 95%CI: [0.63 to 0.88], respectively). Lack of RPLND was associated 
with a 7-fold increase in death in non-seminoma patients (p<0.001).   
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3 Paper III: Reproduction Rates After Cancer Treatment: Experience 
From the Norwegian Radium Hospital  
 
3.1 Identification of study population 
 
Three Norwegian registries (The NRH`s patient registry, MBRN and CRN) were merged for 
identification of eligible cancer patients (“Cases”), all born after 1950, aged between 15–44 
years at diagnosis of invasive cancer and treated at the NRH between 1971–1997.  
To create the comparison group (“Controls”), each Case was gender and birth-year matched with 
five randomly selected individuals from the Norwegian Population Registry, alive and with no 
record in the CRN at the time of diagnosis for the case.  
3.2 Study design and statistical methods 
 
The first post-diagnosis reproduction (PDR) was the primary endpoint of all analyses and 
was here defined as any pregnancy terminated at least 8 months after the date of diagnosis. PDR 
refers to the event of any post-diagnosis childbirth independent of the pregnancy’s duration or 
outcome (therapeutic or spontaneous abortion, stillbirth or living child) as recorded in the 
MBRN.  
Each individual of the Control subunit was assigned the same date as the date of cancer 
diagnosis of his or her Case (for simplicity included in the term “Date of diagnosis”). Each 
patient and his/her Controls were identifiable so that it was possible to fit a model stratified by 
matched set. All individuals were followed from the date of diagnosis to the date of their first 
post-diagnosis reproduction, date of death, emigration or to June 30th, 2004 (cut-off date of the 
study), whatever occurred first. Females were censored at the age of 50. 
Comparisons between patients and the Control group with regard to their post-diagnosis 
reproduction (PDR) were analysed with Cox proportional hazards regression and reported as 
hazard rate ratios (HR) with 95% confidence intervals (CI) and cumulative rates. The analyses 
were adjusted for age at diagnosis and by gender, pre-diagnosis parenthood and diagnosis before 
and after 1988.  The probability of initiating a pregnancy with death treated as censored was 
calculated with the Breslow estimator. Since the proportional hazards assumption did not hold, 
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separate models were fitted for each gender and pre-diagnosis parenthood (none and ≥1 child). In 
addition, all analyses were performed separately for those diagnosed before 1988 (‘pre-1988’) 
and after 1987 (‘post-1988+’, 1988 included)   due to significant treatment alternations and 
anticipated changes in reproduction pattern.  
3.3. Results 
 
A total of 6.071 Cases (females: 55 %, males: 45%) and 30.355 Controls were identified. About 
60% of the Cases were diagnosed after 1987. Compared to Controls, reproduction among Cases 
was significantly reduced both for females and males. The overall HRs were HR=0.45, 95%CI 
[0.39 to 0.51] and HR=0.71, 95%CI [0.64 to 0.78] for females and males respectively. The most 
favourable HRs were always seen in pre-diagnosis childless patients. Fertility-preserving 
attempts after 1988+ have been successful for selected diagnoses, such as ovarian, cervical and 
testicular cancer patients with at least one child prior to the diagnosis. For pre-diagnosis childless 
Cases fertility improvement after 1987 did not reach statistical significance. 
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4 Paper IV: Reproduction after Cancer: a Population-based matched 
cohort study 
 
4.1 Identification of study population  
 
After necessary exclusions, all men and women registered in the CRN from 1967 to 2004 
were included, with the first histologically verified malignancy at age 16 to 45 years and born 
after 1950. All invasive malignant neoplasms and all intracerebral tumours were included, except 
basal cell carcinomas.  
For the tumour-specific analyses some restrictions were made regarding stage due to the manner 
this variable is recorded in the CRN. Only stage I patients were considered for analyses of 
cervical cancer. In some of the sub-analyses, ovarian cancer was categorised into epithelial stage 
I and germ cell or sex-cord tumours of local or locoregional stage. The level of education 
achieved at the time of cancer diagnosis (or assigned diagnosis for controls) was supplied from 
SSB. 
4.2 Statistical methods 
 
To create matched sets comprising of a case and five gender- and age-matched controls, the same 
approach was applied as described in Paper III. Follow-up was defined as the time from the 
actual or assigned date of diagnosis to the date of the first post-cancer birth, date of death or 
emigration, age 46 or December 31, 2006, whichever occurred first.  Cox proportional hazards 
models were fitted to compute overall reproduction hazards rates for both male and female 
cancer survivors compared to the age- and gender-matched controls. Proportional hazards 
assumptions were checked by visual inspection of log-log plots. The models were fitted 
separately for each gender and selected diagnoses and stratified by matched set (a patient and 
his/her corresponding five controls). 
The hazard rates (HR) with 95% confidence intervals (95% CI) were adjusted for age at 
diagnosis through the matching. Further, adjustments for pre-cancer parity and educational level 
at diagnosis were made in all analyses. In addition, we performed sub-analyses for selected 
diagnoses where we stratified by diagnostic periods (based on changes in treatment strategies 
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during the study period), and by extent of disease and pre-cancer parity. Cumulative 
reproduction curves were derived using a competing risk approach. 
4.3 Results 
 
In total, 27,556 cancer patients were analysed (11.451 males and 16.105 females). 
Compared to their controls, male cancer survivors’ reproduction was significantly reduced by 
26% (HR=0.74, 95%CI [0.71 to 0.78]), the comparable figure for females being 39% (HR=0.61, 
95%CI [0.58 to 0.64]). Post-diagnosis fertility rates did not differ between patients and their 
controls for malignant melanoma and thyroid cancer, and the lowest rates were seen for acute 
leukemia, cervical and breast cancer patients.  
Increased reproduction rates during the study period were detected for selected malignancies: 
ovarian cancer HR=0.19, 95%CI[0.11 to 0.32] and HR=0.67, 95%CI[0.49 to 0.90]) between 
diagnostic periods 1967-1987 and 1988-2004, respectively;  for TC survivors  HR=0.61, 
95%CI[0.43 to 0.86] and HR=0.76, 95%CI[0.70 to 0.83], between 1967-1979 and 1989-2004, 
respectively and finally for male HL survivors HR=0.68, 95%CI[0.53 to 0.87] and HR=0.87, 
95%CI[0.73 to 1.04], between 1967-1987 and 1988-2004, respectively.  Pre-diagnosis parity did 
not influence male survivors’ reproduction, whereas females had higher reproduction rates when 
childless at diagnosis. 
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V. Discussion 
 
As the principal author of this thesis is a statistician, the medical aspects will not be the main 
focus of this section, whereas the statistical methods will be discussed in more depth. 
1 Clinical aspects 
1.1 Paper I 
Proportion cure models can be used to estimate the proportion of cured cancer patients, median 
survival time of fatal cases and changes in these two estimates over time. We believe that these 
changes mainly reflect changes and hopefully improvement in cancer care. As opposed to 
medical curability which is very hard to define, the concept of statistical cure is easy to explain 
and possibly intuitive to understand. Patients that are considered statistically cured have the same 
level of relative survival as seen in the general population. However, the absolute estimates of 
the cure proportion are speculative, particularly for cancer sites where medical curability is not 
anticipated.  
The statistical model described in Paper I demonstrates a good concordance between the 
statistical and clinically anticipated curability for 15 of 23 initially selected cancer types. 
 Preliminary evidence suggests that the cure models perform best when mortality is 
neither very low nor high, as confirmed in our study. Of note, compared with the non-cancer 
population, some patients with selected cancer types  may be at an increased risk of death  for a 
long time after 5 years, reaching the general population’s level of mortality after 7–8 years when 
they are “statistically cured”( for example colon and bladder cancer survivors).  For other groups 
of cancer patients, statistical cure could not be estimated with a  follow-up of 15 years ( breast 
cancer) in agreement with the clinical experience of  the continuous risk of late recurrences for 
this cancer type. However, the cure model did not fit for eight cancer types which are known to 
have high 5- and 10-year survival rates such as testicular and thyroid cancer and malignant 
lymphoma. In these cancer patients the level of mortality is low and similar to that in the general 
population. Statistical cure could not be estimated for patients with cancer of the mouth and 
pharynx, a group of patients who can be cured medically. These patients have a very high risk of 
second cancer and a high mortality due to other, non-malignant co-morbidities, such as 
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cardiovascular disorders. Thus this patient group can never be considered statistically cured as 
their mortality is always higher than mortality of the general population.    
Compared to the period 1963–1967 and the period 1998–2002, we document an increase of the 
proportion of statistically cured patients, in particular those with bladder cancer and CNS 
tumours. We believe that these positive changes mainly reflect improvement in cancer care in 
correspondence with the decreased mortality rates for selected cancer sites as HL, TC and BC 
(Cancer of Norway, 2008). 
Our data on bladder cancer should, however be viewed cautiously as they may be related to 
changes in administrative routines in the CRN. From early in the 1970s non-invasive bladder 
tumours were no longer separated from invasive tumours. Both tumour types were included into 
the ICD-7 code 181. An obvious consequence of this change in registration routines was a 
seemingly reduced mortality in patients with bladder cancer.  
What is the clinical interpretation of our estimates of statistical cure? The results from our cure 
model provide us with information about certain patient groups; given their diagnosis there is a 
certain proportion of patients that will survive their cancer and will from a certain time point 
have the same level of mortality as seen in the general population. In oncological practice most 
clinicians will appreciate the possibility to communicate with their patients about this aspect.  
In addition, using the cure model, we are able to estimate median survival time of fatal cases. 
The increase of time to death for patients with “fatal cancer” is valuable for clinicians as it 
proves in a population-based sample the efficacy of life-prolonging palliative therapeutic tasks 
increasingly used during the last 3 decades. However, some limitations of the cure model have to 
be considered. As the model is based on relative survival, no information is provided about the 
causes of death. This model, as applied in Paper I, does not separate the results according to 
known prognostic factors as extent of the disease and age. Further, we can only speculate 
whether any increase of the cured proportion is due to an improved treatment or if it is related to 
earlier diagnosis for example as a result of screening.   
Finally, in our view, the interpretation of the results derived from the cure model require a close 
co-operation between statisticians and clinicians who understands the clinical course of the 
disease and have detailed knowledge about the treatment and diagnostic procedures and its 
changes. 
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1.2 Paper II   
 
TC-specific mortality is doubled among patients diagnosed with either seminoma or non-
seminoma after age 40, even when initial EOD is taken into account. Among men with non-
seminoma, non-white race and decreasing SES also significantly increases TC-specific mortality. 
Most oncologists consider germ cell TC as a disease of young men, aged less than 40 years. 
Though this is true, one important finding of our study is that 26% of patients are older than 40 
years, some of them even in their 70s and 80s. In the oldest patients pathologists and clinicians 
should, however, be aware of the possibility of misclassification, as malignant lymphoma is a 
frequent cause of a testicular tumour in higher age (Koukourakis, et al., 2010).  
 There is a higher risk of “older” patients with TC to die of their malignancy. One may question 
whether an age of 40 years as used in the present study is the most appropriate cut-off age. We 
chose this age with the background in the well-known clinical recommendation to avoid 
bleomycin in men above the age 40 years, in spite of the recognition that this drug is an essential 
component of cisplatin-based chemotherapy (Horwich, et al., 2006; Simpson, et al., 1998; 
O'Sulivan, et al., 2003). As no information is available in the SEER registry about chemotherapy 
it cannot be decided how much the eventual omittance of bleomycin represented a cause of 
inferior TC-specific survival in our “older” patients. Most probable the shown age-related risk of 
TC–related death is due to overall less intensive treatment.  
Our education variable “EDUC” reflects primarily the level of education within the patients’ 
county of residence. Preferably one should have used the individual patients’ education level at 
the time of diagnosis. This information was not available in the SEER registries. The use of 
“EDUC” class as a surrogate of an individual’s SES thus requires the acceptance of two 
assumptions: 1.The educational level of a geographical area (a county) reflects the area’s SES. 2. 
The county’s SES is a surrogate for an individual’s SES. The first assumption has been verified 
by Paasche-Orlow (Paasche-Orlow, et al., 2005), and has also been the basis of  Hoffman et al. 
study  (Hoffman, et al., 2008), who showed that seminoma patients from US areas with low 
levels of education  at a decreased level were offered radiotherapy compared to those from 
geographical areas with higher education. The second association has been demonstrated for 
cancer patients in general by  (Kravdal, 2006) for Norwegian patients and, for TC patients by 
Power et al. (Power, et al., 2001) Also Boyle`s (Boyle, 2003) observations from Eastern 
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Germany and a recent report from Estonia  (Aareleid, et al., 2010) indicate  reduced survival in 
TC patients living in areas with considerable socio-economic problems.  
The observation that mortality decreased with increasing calendar-year periods of diagnosis is 
encouraging. Power et al showed a similar development: in Wales the association between SES 
and the survival was reduced when comparing patients diagnosed between1971–1975 and those 
diagnosed between 1986–1990. This observation and our results are most probably associated 
with better availability of modern treatment of TC, even for patients of low SES. Improvement 
of TC specific survival in the most recent calendar years also reflects improved knowledge 
among clinicians how to apply new cytostatic drug combinations optimally and how to avoid 
toxicity, the later aim of particular relevance for “older” patients. The omittance of RPLND had 
a stronger negative effect in non-seminoma patients compared to the patients with seminoma. 
However, these observations should be cautiously interpreted due to the fact that only initial 
treatment was recorded. There is a non-quantifiable risk that post-chemotherapy surgery is 
insufficiently recorded. 
Admittedly the shown survival differences in Paper II are small. They are greater among patients 
with non-seminoma than in those with seminoma. These differences between the two major 
histological types are associated with inherent differences of tumour biology as for example 
expressed by different stage distribution at diagnosis, different radiation sensitivity and different 
risk of post-diagnosis metastatic property. This again is associated with a higher level of 
treatment complexity in non-seminoma versus seminoma patients requiring more economic 
resources and a higher level of competence of the medical team taking care of patients with non-
seminoma.  
1.3 Paper III and IV 
 
In Paper III, post-diagnosis reproduction of patients referred to a tertiary cancer centre is below 
that of the general population and influenced by gender, type of malignancy, pre-diagnosis parity 
and diagnostic period, with more favourable rates in males than in females. Improved 
reproduction rates were observed post 1988+ for patients with selected genital cancers and males 
with Hodgkin’s lymphoma.  
The results from Paper IV based on unselected patients from CRN show similar results as in 
Paper III with post-diagnosis reproduction rates which are lower in cancer survivors than in the 
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general population. Exceptions are patients with thyroid cancer and malignant melanoma for 
whom the reproduction rates were similar to those of the general population. Improvement in 
post-diagnosis reproduction rates in the last decade of the previous century are at least partly 
related to attempts of fertility preserving treatment.   
Cure is the primary aim of all treatment in young cancer patients, but oncologists have 
increasingly become aware of survivorship issues (Ganz, 2009; Aziz, 2006), post-diagnosis 
reproduction being one of them. For example at the NRH about 70% of the TC patients 
(Magelssen, et al., 2005) opted for pre-treatment semen cryopreservation, in agreement with 
Schover et al`s experience (Schover, 2009). Brydøy et al (Brydøy, et al., 2009) described that 
39.% of ≥5 year TC survivors attempted post-diagnosis fatherhood, the comparable figure being 
45% among  male and 50% among  female HL patients (Kiserud, et al., 2007). 
At the outset of this thesis we were interested not only in post-diagnosis reproduction of cancer 
patients but also in cancer patients’ overall ability after their treatment to initiate a pregnancy. 
Therefore we included miscarriages and stillbirths into Paper III. Our figures for early abortions 
might, however represent underestimations, both for patients and their controls. We therefore 
decided not to include the number of abortions in Paper IV. Other reasons for falsely high 
estimates of male post-diagnosis reproduction may be that the recorded father was not the 
biological father, in particular as donor inseminations are not recorded. Further, some mothers 
might have chosen not to reveal the fathers identity. 
During the work with Paper III and IV, two other population-based studies have been published, 
one from Norway and one from Finland. Syse et al`s (Syse, et al., 2007) followed patients with 
adult-onset cancer identified by the CRN up to 2001. The included patients were born from 1935 
to 1984 and they were followed to December 2001. The endpoint was post-cancer reproduction 
as recorded in the Norwegian Population registry which does not record miscarriages, abortions 
or stillbirths. Syse et al demonstrated that the post-cancer reproduction rates for both genders 
were reduced by approximately 25% compared to the general population. These authors also 
showed that post-diagnosis reproduction increased among patients diagnosed during the last 2 
decades of their study period. The reasons for the difference between Syse et al’s and our 
reproduction rates published in Paper IV have been intensely discussed. The following 
explanations seem reasonable and plausible. The selection of cases and their controls differ: Syse 
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et al’s studied individuals born from 1935 to 1984, whereas all of our cases and controls were 
born after 1950.  
Post-diagnosis reproduction of cancer patients, who had died before 1965 has thus not been 
included in Syse’ et al’s report. In contrast, we had information on complete reproduction history 
in all individuals included in our study, assuming that no pregnancy was initiated before the age 
of 16 for any of these individuals. Our comparison group consisted of five age- and gender-
matched individuals selected at random from the general population whereas Syse et al used data 
from the entire general population. Using five controls instead of the whole population might 
have caused a loss in efficiency, however this loss is considered very small and negligible. 
Further, Syse et al included childhood cancer survivors whereas our sample consisted only of 
adult-onset cancer patients. 
Finally, the inclusion of older birth cohorts in Syse et al’s study reflects to a larger degree an 
‘old-fashioned’ treatment of cancer patients compared to the treatment being given to patients 
included in Paper IV. We assume that most of the patients with advanced disease that were 
treated during the 50ties to 70ties when effective chemotherapy was rarely available, would most 
likely have died before they had a possibility to initiate a pregnancy. On the other hand patients 
who had survived could have become parents after end of cancer treatment of their (most likely) 
localized disease. In contrast, in the 80ties and 90ties of the last century effective chemotherapy 
and combination treatment strategies have been developed and young cancer patients with 
advanced disease were more likely to survive but at the expense of impaired fertility. We thus 
speculate that a larger proportion of cancer survivors with a more advanced disease and a more 
intensive treatment could lead to lower overall post-diagnosis reproduction rates.  We therefore 
conclude that the differences between Syse et al’s and our report are mainly related to the 
differences in the two study cohorts.  
In the second study from Finland (Madanat, et al., 2008), the authors evaluated the post-
diagnosis reproduction in cancer patients aged 0–34 years at diagnosis. Similar to the report by 
Syse et al., the Finnish study was based on information from the Finnish Population Registry 
Center. Siblings were used as controls. The post-diagnosis reproduction rate for at least one child 
was reduced by 54% in females and by 43% in males.  
The overall low post-diagnosis reproduction rates in the Finnish study are in agreement with our 
results. Also the Finnish started their observation time 9 months after the malignant diagnosis, 
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which we consider appropriate. As in our Paper IV female cancer patients’ post-diagnosis 
reproduction was found below that of males. But again, the selection of patients differs from our 
studies, as childhood cancer patients were included in the Finnish report.   
We refrain from direct comparison of the results from Paper III and IV due to the different 
patient selection and some differences in the statistical methods.  However, the different findings 
of the effect of pre-diagnosis parity in male cancer patients need to be commented on; in Paper 
III, pre-diagnosis childless men had a higher post-diagnosis reproduction rates compared to those 
with at least one child prior to the malignant diagnosis. Such a difference was not observed in 
Paper IV.  It might be that childless young men with cancer diagnosis and strong desire of post-
diagnosis fatherhood have selectively been referred to the NRH where fertility-saving treatment 
including semen cryopreservation generally were introduced 2–3 years before these tasks 
became standard in the country elsewhere.  
Due to selection bias as to the wish of post-diagnosis parenthood, it is neither justified to 
compare the results between mono-institutional studies or compare results from different 
institutions with population-based studies. This refers, in particular, to studies which are 
restricted to patients who attempted post-diagnosis reproduction (Brydøy, et al., 2005; Kiserud, 
et al., 2007; Behringer, et al., 2005) versus population-based studies.   
Paper III and IV contain information valuable in the pre-treatment communication between 
clinicians and new patients with adult-onset cancer. Specifically, our results enable clinicians to 
estimate the chance of post-diagnosis parenthood for selected diagnoses, though recognizing that 
the majority of our estimates of PDRs document treatment applied during the last three decades 
of the 20th century. The figures for post-diagnosis reproduction shown in Paper III and IV  may 
thus be lower than those achievable today after  the introduction of new techniques for fertility-
saving (cryopreservation of ovarian tissue, testicular sperm cell extraction (Shufaro, et al., 2010; 
Salihu, et al., 2003). In addition, treatments of adult-onset cancers are in continuous development 
affecting a cancer patient’s post-diagnosis reproduction. The more frequent use of the 
surveillance policy in non-metastatic TC patients will also lead to increased production in these 
patients (Pagliaro, 2010). On the other hand, more intensive treatment in other malignancies will 
reduce the chances of post-diagnosis reproduction as for example the introduction of new 
chemotherapy regimens in Hodgkin`s lymphoma  (Evens, et al., 2008) or the 5 years application 
of anti-estrogens in breast cancer patients. (Zervoudis, et al., 2010; Muss, 2001) 
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2 Statistical considerations 
2.1 Matching 
Matching is a design feature where a subject of interest, here called an index case, is assigned a 
number of subjects that are equal, or similar, to the index subject with respect to matching 
variables. Typical matching variables are sex, age, year of birth, social class and area of 
residence.  
The simplest form of matched data is paired data, where one individual is matched to the index 
case, and the difference between the index cases and their matched controls is assed with a 
paired t-test instead of comparing the individual outcomes for index subjects and controls.  In 
this way one can adjust for systematic difference between individuals. Generally, with other 
types of outcomes and more subjects matched to the index case one may often apply simple 
analytical methods that take care of systematic differences due to the matching variables.  
One should distinguish between matched cohort studies, used in Paper III and IV, and matched 
case-control studies. In a matched case-control study the index cases are the individuals who 
experience  the outcome of interest (response) of the study, typically a disease, and the matched 
controls are disease free individuals that are equal (similar) to the cases on the matching 
variables. Specially designed methods are required to analyze matched case-control data.  
In a matched cohort study, on the other hand, the index cases are individuals exposed to a certain 
risk factor and the matched subjects are individuals without this exposure that are similar to the 
index subject with respect to the matching background variables. The outcome in a matched 
cohort study could be some future event. In the matched cohort we thus achieve balance between 
the exposure variable and the matching variables.   
 In Paper III and IV the exposure variable is a cancer diagnosis and the matched subjects are thus 
individuals without cancer (at the time of diagnosis of their index case). The outcome of interest 
is a future reproduction, or more specifically, time to reproduction. The aim is not to study what 
caused the cancer, but rather how cancer effected reproduction, and the cancer diagnosis is the 
main exposure variable of the study, whereas the matching variables are considered as 
covariates.  
When designing our studies for Paper III and IV, we had two possibilities: we could match our 
index cases with a given number of cancer free individuals or we could have conducted a full 
cohort study involving all individuals in the Norwegian population. However, the chosen time-
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scale for both of our studies was time from cancer diagnosis. For subjects free of cancer this 
time-scale would not apply without assigning a ‘time of diagnosis’ and this assignment was 
made possible with matching on year of birth and start of follow-up from the date of cancer 
diagnosis of the index case.  
Still, a study using the complete Norwegian population could have been possible, matching all 
available cancer free individuals to the cancer survivors (index cases) on year of birth and being 
alive at time of diagnosis of the index subject. However, it was considered that a study with five 
subject matched to each index case was statistically sufficiently efficient. The data sets then 
became much smaller than what the complete population data would have been and were much 
easier to deal with computationally. 
Reproduction is strongly age and birth cohort dependent. An analysis that ignores these factors 
may be flawed. With our  design, based on a cancer case (index case) matched to five cancer free 
individuals, it was possible to analyse the data with Cox-regression stratified on matched sets as 
was done in Paper IV. Such analyses are based on very flexible simultaneous modeling of age 
and year of birth. 
 However, in many instances it is sufficient to only include main effects of these variables, as 
was done in Paper III.  Under a more specific model, for instance including the matching 
variable in a regression, a valid and sometimes more efficient analysis of the association between 
the main exposure and the outcome is possible. One needs to bear in mind that the choice of the 
model always depends on the actual data and alternative models might still give a good fit but it 
might be more difficult to model the matching variables correctly. On the other hand, dissolving 
the matched set or changing their size might lead to a more flexible modelling of the covariates. 
When analysing data for Paper III, we have investigated several scenarios concerning the size of 
matched set. We have fitted Cox models stratified by the matched set, stratified by a larger set 
constructed of all patients and controls born in the same year and during the same five-year 
period. Finally, also a model where matching was ignored and where one adjusted for age as a 
covariate was fitted. As can be seen from Table 4, the differences between HR and the 
corresponding CI estimated using stratification by matched set and adjusting for age as a 
covariate are very small. So the final analysis performed on data in Paper III models age at 
diagnosis as a continuous variable and all models are fitted separately for males and females. 
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Table 4: Cox regression adjusted for age at diagnosis vs Cox regression stratified by matched set 
 Total number of 
cancer patients 
 
M          F 
4238      6940          
Reproduction after cancer,  
HR [95% CI] 
Cox regression adjusted for 
age at diagnosis 
M                         F 
Reproduction after cancer,  
SHR [95% CI] 
Cox regression stratified by 
matched set 
M                            F 
Breast cancer  4,061  0.36 
[0.30 to 0.43] 
 0.35  
[0.29 to 0.42]] 
Cervical cancer 
stage I 
 1,970  0.35 
[0.30 to 0.40] 
 0.33 
[0.29 to 0.39] 
Ovarian cancer 
stage I 
 402  0.48  
[0.38 to 0.62] 
 0.50 
[0.38 to 0.64] 
Testicular cancer 3,511  0.75 
[0.70 to 0.79] 
 0.74 
[0.69 to 0.79] 
 
Hodgkin’s 
lymphoma 
727 507 0.90 
[0.78 to 1.02] 
0.70 
[0.59 to 0.83] 
0.88 
 [0.76 to 1.00] 
0.66  
[0.56 to 0.79] 
 
2.2 Representativeness 
 
In epidemiology, representativeness is a major concern for consideration of external validity: 
How well does the study sample represent the population of interest?  
In cancer patients, the majority of studies on late effects as reproduction and survival are based 
on data that goes far back in time. One evaluates treatments and social situations which may no 
longer be valid in cancer patients today. This limitation with regard to generalisability of our 
results to a current cancer patients’ population must always be kept in mind. On the other hand, 
our conclusions drawn from older data might still lead to a better understanding of biological 
phenomena as recovery of spermatogenesis after chemotherapy or of the role of SES for survival 
of cancer patients.  
Further, the results from Paper II reflect the American situation, where differences as to race, 
SES and availability of health care service most certainly differ from the situation in Europe and 
in the Nordic countries. 
Therefore, the conclusions drawn from Paper II may be limited to countries with a similar social 
structure and availability of heath care service as it is in the USA. On the other hand, our results 
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clearly show that both age and SES are important factors that impact on survival, although they 
are not often considered in analyses performed by medical professional. 
The question regarding generalisability is also of interest for patients of Paper III; Table 5a and 
5b  clearly shows that between 1971 and 1997, only 1/3 of the country patients during the study 
period have been treated at the NRH and that there are great differences in the proportions of 
treated patients depending on the actual cancer diagnosis.  For example, large proportions of 
patients with malignant melanoma, thyroid and breast cancer were not referred to the NRH as 
their treatment can be applied at the community hospitals. On the other hand, patients with 
Hodgkin’s lymphoma and gynecological cancers have been preferably treated at the NRH.  
Patients from Paper III are thus representative for patients seen at the NRH, which is the leading 
Oncological Center in Norway and is supposed to provide the most up-to-date treatment at any 
time available for patients in need of chemotherapy or radiotherapy including fertility-saving 
treatment modalities. We believe that our observations thus reflect the results as to post-
diagnosis reproduction which can be achieved among all patients referred to a large academic 
oncological unit in Europe. However, they may not be completely representative for a population 
of unselected cancer patients identifiable in national cancer registries. 
The results in Paper IV are representative for all patients with adult onset cancer. They reflect the 
post-diagnosis reproduction rates achievable in Scandinavian countries with a public healthcare 
service covering most of all expenses related to cancer treatment. This cohort also comprises 
cancer diagnoses usually not treated at NRH or only limitedly seen at a tertiary referral 
oncological center. 
Also the representativeness of the control groups in Paper III and IV has to be considered. The 
only criteria for the matching performed were age, gender and being cancer-free at the date of 
diagnosis for the relevant case. Place of residence, education and partnership are also important 
factors for reproduction but were not available for analyses. As education and partnership are 
associated with reproduction, as shown by Kravdal (Kravdal, et al., 2008) for a Norwegian 
cohort, these variables should have been taken into account and adjusted for as covariates in the 
analyses. In this connection it is of interest that Syse et al found an increased divorce rate (Syse, 
et al., 2007) among men with a TC diagnosis. On the other hand, Kravdal reported only a 
minimal effect of education on cancer survivors. For subgroups of patients the educational level 
seems to be associated with post-diagnosis reproduction, as shown in Paper IV. 
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Patients treated at NRH and elsewhere in Norway between 1971 and 1997, aged 16 to 45 at 
diagnosis 
 
Table 5a: Males 
Cancer diagnosis Not treated at NRH Treated at NRH Total 
Hodgkin’s lymphoma 167 (34%) 320 (66%) 487 
Testicular cancer 1154 (54%) 1000 (46%) 2154 
Malignant melanoma 779 (84%) 152 (16%) 931 
Colon ca. 177 (89%) 21 (11%) 198 
Thyroidea 109 (72%) 43 (28%) 152 
Other 2086 (68%) 960 (31%) 3046 
Total 4477 (64%) 2499 (36%) 6976  
 
Table 5b: Females 
Cancer diagnosis Not treated at NRH Treated at NRH Total 
Hodgkin’s lymphoma 116 (36%) 202 (63%) 318 
Malignant melanoma 1453 (89%) 171  (10%) 1624 
Cervix, stadium I 336 (35%) 635 (65%) 971 
Ovarian, localised 107 (39%) 164(60%) 271 
Breast ca.  1390 (72%)  551 (28%) 1941 
Colon ca. 184 (84%) 35 (16%) 219 
Thyroidea 489 (81%) 114 (19%) 603 
Other 2065 (63%) 1233 (37%) 3298 
Total 6140 (66%) 3105 (34%) 9245 
 
 
Cause specific survival versus competing risk models 
Introduction 
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Standard survival data measure the time span from some time origin until the occurrence of an 
event of interest. If several types of events occur, a model describing progression to each of these 
competing risks may be needed. The interest in competing risk modelling goes as far back as the 
18th century, when Bernoulli studied the possible consequences of eradication of smallpox on 
mortality rates. The problem of estimation of failure probabilities after elimination (or 
modification) of one of the competing risks has been of great importance and a subject of much 
debate since the 1970s and many new perspectives, models and methods to analyze such models 
have been developed over the last two decades.  
Typically, one type of event is the event of interest; however, other competing event types might 
prevent the event of interest from occurring (Figure 6). In Paper II and IV the main event is post-
diagnosis reproduction and the competing event is death. In Paper II the event of interest is the 
cause-specific TC mortality and the other type is death of all other causes. 
 
 
 
 
 
 
 
 
 
 
Figure 6: The competing risk model for two competing events where hj(t) is the hazard for 
transition to state j. 
Caution is needed for analyses of the event of interest occurring in the presence of these so-
called competing risks. Treating the competing events as censored observations may be difficult 
to interpret.  For instance the Kaplan-Meier estimate (KM) that treats the competing risk as 
censoring, could be interpreted as the survival function if the competing risk could have been 
eradicated. Furthermore, this would require that the event of interest and the competing risk were 
independent, which is a dubious and unverifiable assumption. The Cox proportional hazards 
1 
Main event 
(childbirth) 
0
Alive 
2 
Event 2 
(death) 
 
h1 (t) 
h2(t) 
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model can still be used, based on the stochastic process scheme in Figure 6, but the interpretation 
of the results would be different from the interpretation when there are no competing events.  
One may argue that a more sensible function to estimate, than 1-KM, is the cumulative incidence 
function (CumInc) i.e. the probability that the event of interest has occurred before time t when 
this event can be prevented from occurring by the competing risk. Figure 7 illustrate a situation 
with one competing risk (death) and one main event of interest (child birth) for selected 
diagnoses (data from Paper IV). When depicting the CumInc for both events (the main event of 
childbirth and the competing event of death) we want to emphasize that both events are modelled 
simultaneously. 
 
  
Figure 7: Cumulative incidence functions depicted for the main event (child-birth) and 
 the competing risk event (death).  
Right censoring and the independence assumption 
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The independence between the event and censoring distribution is often assumed without further 
consideration, but it might easily be violated. There are several reasons for right censoring: 
 End of study. We only have information on the individuals enrolled in a study until a 
certain point in time. Therefore, some individuals are not followed up long enough for the 
event of interest to occur. This type of censoring is often called administrative censoring. 
 Loss to follow-up: an individual previously enrolled in a study has left the study, possibly 
due to migration or study fatigue. He or she might experience the event of interest, but we 
do not have any information about it. 
 Competing risk: another event has occurred which prevents occurrence of the event of 
interest. 
When censoring is due to ending of study, we can in general safely assume the assumption of 
independence is fulfilled and the censoring is not informative. However, in the other two 
situations (loss to follow-up and competing risk), one should be cautious. 
For example some patients enrolled in a study might get healthy during the follow-up and lose 
their interest in the study. Censoring such individuals would cause a downward bias of the 
estimated survival curve, which means that the probability of the event of interest will be 
overestimated. An opposite situation might also occur; some individuals are too ill to continue 
participation in the study and are censored at the time they decide to drop out. Here, such 
censoring will cause an upward bias and the probability of the event of interest will be 
underestimated.  
Censoring due to a competing risk is even more problematic. When only the first event can be 
observed it is not possible to address the question of whether the times to the two events are 
independent. Thus estimates under the independence assumption cannot be interpreted are 
difficult to explain.  
An explanation in terms of the stochastic process scheme in Figure 6 is however possible. The 
cumulative hazard H1(t) is the integral of the hazard h1(t) for transition to state 1. In presence of 
censoring due to end of study this may be estimated by the Nelson-Aalen (NAa) estimator. The 
KM estimate will then be approximately equal to exp(-NAa) and have interpretation exp(-H1(t)), 
but admittedly it is difficult to explain what this means in simple language. It is, however, 
possible to show that 1-KM will be larger than the estimate of CumInc under presence of 
independent censoring (due to end of the study).  
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Figure 8 depicts both the CumInc and 1-KM estimates for breast cancer (left) and testicular 
cancer. There are still many women who do not survive their breast cancer, especially those 
diagnosed at a young age so the difference between CumInc and 1-KM is very large. The 
treatment of testicular cancer has been very successful after new therapies have been introduced 
in the 1980s so the number of deaths as a competing risk is much smaller for these diagnoses and 
the difference between the two estimates is much smaller. 
Some authors argue that in the presence of competing risk,  1-KM should never be used, even if 
the number of competing risk events is relatively small and the two estimates (1-KM and 
CumInc) are likely to be very similar (Crowley, et al., 2006). In addition, it is important to bear 
in mind that the discrepancy between 1-KM and CumInc is dependent on the timing and 
frequency of the failures from a competing risk; the earlier they appear and the more frequent 
they are, the larger will be the difference between 1-Km and CumInc. Two situations are 
illustrated in Figure 8: many patients diagnosed with breast cancer die of their cancer so there are 
many competing events (deaths). In contrast, a great majority of TC cancer patients survive so 
there only a few deaths competing with the main event (post-diagnosis reproduction).  Therefore 
it is important when analysing and presenting results from an analysis involving competing risk 
to describe probabilities of failure not only from the event of interest, but also from failures from 
a competing risk event(s).  
 
  
Figure 8: Differences between cumulative incidence (CumInc) and 1-Kaplan-Meier estimates 
2.2.1 Comparisons between different modelling approaches  
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Cox regression and competing risk regression 
 
As explained above, a great deal of caution has to be used when depicting the CumInc function 
in the presence of competing risk. However, the HR estimates computed using Cox regression 
and Competing risk regression (Fine, et al., 1999) are very similar for our data used in Paper III 
and Paper IV as illustrated in Table 6 (data from Paper IV). For breast, cervical, ovarian and 
testicular cancer both the point estimates of HR and SHR and their corresponding 95% CI were 
almost identical. For Hodgkin’s lymphoma, the estimates were very similar for females but 
slightly different for males. However, the difference is small and negligible.  
Still, one has to keep in mind that the two approaches are theoretically different. The more 
traditional approach would be to apply Cox regression treating the competing risk as censoring. 
In this case one analyses the cause-specific hazard h1(t). Using the other method, one models 
hazard derived from treating the CumInc as an (improper) cumulative distribution function with 
a proportional hazards model. 
 
 Total number 
 
 
 
M               F 
Reproduction after cancer, 
 HR [95% CI] 
Cox regression stratified by 
matched set 
M                         F 
Reproduction after cancer, 
 SHR [95% CI] 
Competing risk regression 
 (Fine & Gray) 
M                            F 
Breast cancer  4,061  0.33 
[0.27 to 0.39] 
 0.31 
[0.26 to 0.38] 
Cervical cancer 
stage I 
 1,970  0.34 
[0.29 to 0.40] 
 0.33 
[0.28 to 0.38] 
Ovarian cancer 
stage I 
 402  0.43 
[0.33 to 0.56] 
 0.44 
[0.34 to 0.57] 
Testicular cancer 3,511  0.68 
[0.63 to 0.72] 
 0.67 
[0.62 to 0.71] 
 
Hodgkin’s 
lymphoma 
727 507 0.79 
[0.69 to 0.92] 
0.61 
[0.51 to 0.73] 
0.74 
[0.65 to 0.85] 
0.62 
[0.53 to 0.72] 
 
Table 6: Differences between Cox regression and Competing risk regression. Both models 
adjusted for age (continuous), parity (3 categories) and educations at diagnosis (3 levels) 
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2.2.2 Summary and concluding remarks 
Modelling the effect of covariates on cause-specific hazards may lead to different conclusions 
than modelling their effect on sub-distribution hazards and cumulative incidence functions. 
However, the standard Cox model can be used to model the effect of covariates on the cause-
specific hazards of the different endpoints (here childbirth or death). Applying the Cox model, 
there is a great advantage of being able to use well-developed theory and statistical software. 
Cause-specific hazards obtained from a Cox model can be translated into cumulative incidence 
curves where such curves are estimated as the sum of all the unconditional probabilities of 
experiencing event from a chosen cause. Unfortunately, there is a problem with such an 
approach–proportionality is lost and the effect of a selected covariate on the cumulative 
incidence curves can no longer be expressed simply as a number. So to determine the effect of a 
covariate on the cumulative incidence of an event of interest, it is important to consider the 
competing risk(s)—both baseline and the covariate effect. Still, results from the Cox model do 
not answer to the question of what the effect of some covariate would have been on the cause-
specific hazard if the competing risks were absent, unless they are independent.   
2.3 Proportion cure models 
Definitions 
 
Relative survival, R(t) is defined as the ration between the observed, S(t) and expected survival, 
S*(t): 
R(t)= S(t)/ S*(t) 
so the relative survival model can be written as follows S(t)= S*(t) R(t). 
Statistical cure can be modelled using two approaches: the mixture and non-mixture model. The 
first one is the most popular and commonly used one, possibly because it is intuitive and easy to 
understand.  
When modelling cure using the mixture model we define an asymptote at the cure fraction, π, for 
the relative survival function R(t) (Lambert, et al., 2007; Lambert, et al., 2007): 
S(t) = S*(t)(π + (1 − π )Su(t)) 
π is the proportion cured (the cure fraction), (1 − π ) is the proportion ‘uncured’ (or those ’bound 
to die’ fatal cases) and Su(t) is the survival function for the uncured individuals.  
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Median survival of the uncured is defined as follows: 
Su(median) =1/2 
In order to fit the model one needs to choose a parametric distribution for S(t). The most popular 
choice is a Weibull distribution with two tuning parameters, λ (for scale) and γ (shape), which 
often provides a good fit.  
If the relative survival curve does not reach a plateau, then the estimate of cure is based on 
extrapolation beyond the time range of the data. In theory, cure occurs when time approaches 
infinity. For practical purposes cure is assumed to be reached when the relative survival function 
of the ‘uncured’ group is below a stated amount, 1% in this study. Estimation of the cure model 
parameters is obtained using maximum likelihood on the individual level data. The estimation 
procedure is similar to that of De Angelis (de Angelis, et al., 1999) but extended to model both 
parameters in the Weibull distribution  (Lambert, et al., 2007).  
The motivation behind non-mixture cure proportion model (Lambert, et al., 2007) is that after 
end of cancer treatment, it is assumed that a cancer survivor still has Ni cancer cells that might 
cause metastases. The distribution of Ni can be modelled with a Poisson distribution with mean θ 
so the cure fraction is defined as a probability of θ equal to zero. When it is not the case, we can 
define time Zj of the jth metastatatic cell needed to produce a new tumour. The times Zj follow a 
distribution: 
Fz=1-Sz(t). 
Now the overall survival can be written as: 
S(t)= π Fz(t) 
Alternatively, the non-mixture model can be rewritten so that it resembles the mixture model: 
S(t) = S*(t)(π + (1 − π )( )) 
 
 
Comparisons between mixture versus non-mixture models 
 
There is a wide range of distribution to choose from when modeling the cure proportion, the 
most commonly used are Weibull, lognormal and Gamma distribution. Both the cure fraction π 
and the parameters in the distributions may vary by covariates. Sposto (Sposto, 2002) described 
three link functions when modelling the covariates X (age in categories and sex): 
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 The identity link: πi=β’X 
This is relatively easy to interpret but may have boundary problems for low and high cure 
fractions. 
 The logistic link log(πi/(1- πi) =β’X 
Covariates are expressed as (log) odds ratios, similar to those in logistic regression. 
 The log(-log) link log(-log(πi)) =β’X 
This link is useful for the non-mixture model.  
 
To study the differences between mixture and non-mixture models and the effect of different link 
functions defined above, we fitted both mixture and non-mixture models with Weibull, 
lognormal and Gamma distribution and identity, logistic and log-log link. All 23 selected cancer 
sites were modeled using these 18 models. The details are listed in the Appendix.  
There were very small differences between estimates derived with mixture and non-mixture 
models both with regards to proportion cured and median time of fatal cases. Overall, the non-
mixture model estimates were slightly lower compared to those from the mixture model 
concerning proportion cured and marginally higher when estimating median time of fatal cases.  
The models converged most often when using the logistic link regardless of the choice of 
distribution and for both mixture and non-mixture models. 
Given the type of model and the choice of distribution, the differences between estimates of 
proportion cure and the median survival of fatal cases computed using different link functions 
are negligible. However, the number of cancer sites when a convergence was achieved depended 
on the choice of link function. 
For the Weibull distribution, the estimates were almost identical for mixture and non-mixture 
models. The model always converged with non-mixture model and logistic link. Using the 
identity link, the convergence was not achieved for cancer sites where medical cure is either not 
expected or questionable. With lognormal distribution, convergence was achieved for almost all 
sites using the logistic link. The estimates of proportion cured were the lowest of all three 
distributions, more so with the non-mixture model. When the model was fitted with the Gamma 
distribution, the non-mixture model gave slightly lower estimates for all sites when both models 
converged. For liver and pancreas the mixture model did not converge for all link function but 
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the non-mixture model always converged. Regarding prostrate, testis, kidney, thyroid and Non-
Hodgkin, none of the models converged for any choice of the link function. 
According to the literature (Lambert, 2007), in most cases it does not matter if one uses the 
mixture or non-mixture models when the aim was to estimate the cure proportion and median 
survival of uncured cases. Our comparison of different distributions and link functions confirmed 
this finding. However, the mixture models are easier to explain and provide estimates of the 
survival function of the fatal cases. On the other hand, the non-mixture models have slightly 
better fit when measured with Akaike information criterion (AIC). Additionally, there are 
documented fewer convergence problems with the non-mixture model. In our study the number 
of non-convergences was the same for the mixture and non-mixture model with the exception of 
Gamma distribution. With this distribution the mixture model had the most convergence 
problems, especially when fitted with the log-log link. 
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I. Conclusions 
 
We have demonstrated in this Thesis that large population-based and hospital-based registries are 
a useful source of information when the aim is to elucidate clinical questions so our principal 
hypothesis was thus confirmed.  However, a close collaboration between the responsible 
statistician and a medical professional is recommended to ensure a correct choice of a statistical 
approach and a valid interpretation of the results.  
 
1. We have demonstrated that proportion cured models can be applied to an unselected and 
large range of cancer types and that the model fit and results are almost unaffected by the 
choice of model (mixture or non-mixture) and the link function. However, the model cannot 
be used for cancer types where the chances of medical curability are very high and the 
anticipated proportion cured over 90%. In addition, the model cannot be applied to cancer 
sites where a medical cure is not anticipated and very late relapses might occur. 
 
2. In addition to the well known role of extent of the disease, age over 40 is independently 
associated with increased TC specific mortality. For non-seminoma patients, high SES also 
plays an important role in decreasing TC mortality. Overall, race, calendar period of 
diagnosis and marital status are independent factors that influenced TC mortality rates. 
 
 
3. Post-diagnosis reproduction rates in cancer patients are lower than the rates of the general 
population and more so in females compared to males. Regardless of the patient selection, 
the rates are influenced by the type of the malignancy and parity. An improvement in fertility 
rates is evident along with the introduction of fertility-saving tasks for selected cancer types.  
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VII. Further projects 
 
Childhood cancer survivors are a growing survivor group for which fertility is an important 
issue. Given a relatively small size of this group, one needs to have an access to large registries 
and long-follow up to be able to investigate post-diagnosis fertility for childhood cancer 
survivors. Further research has to be aimed to elucidate post-diagnosis reproduction – both using 
the information available in large registries but also using information obtained from surveys so 
that also a patient’s wish and interest in starting a family can be considered.   
 
Another much debated issue is sub-fertility of testicular cancer patients before their diagnosis. 
There have been several studies linking testicular dysgenesis syndrome and sub-fertility but there 
is also growing evidence that a large proportion of TC patients does not have lower pre-diagnosis 
fertility (Kim, et al., 2010; Akre, et al., 2009). This issue is currently being investigated in 
Norwegian cancer patients and a preliminary report by Oldenburg and Cvancarova has been 
presented at 7th Copenhagen Workshop on CIS Testis and Germ Cell Cancer. Our group will 
continue working on this project since more research is needed to investigate this issue in depth.   
As we indicated in Paper II, SES has an impact on survival of good prognosis TC patients from 
the USA. The role of SES for cancer patients in general should be examined in more detail also 
in countries with well developed and organised health care service as in Europe and especially in 
Scandinavia using SES available on an individual level.  
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Appendix :  
The mixture model with various link functions 
a) Proportion cured 
Weibull Lognormal Gamma
identity logit log-log identity logit log-log identity logit log-log
mouth,pharynx 0,428404 0,428404 0,428404 0,35149 0,35149 0,351492 0,180004 0,180004 nc
oesophagus 0,120127 0,120127 0,120127 0,091727 0,091727 0,091727 0,108318 0,108318 0,108318
stomach 0,227016 0,227016 0,227016 0,182081 0,182081 0,182081 0,194376 0,194376 0,194376
colon 0,574275 0,574275 0,574275 0,481947 0,481947 0,481949 0,575464 0,575464 0,575464
rectum 0,601867 0,601867 0,601867 0,519637 0,519637 0,519637 0,605338 0,605338 0,605338
liver 0,103683 0,103683 0,103683 0,073499 0,073499 0,073499 nc nc nc
gallbladder 0,171404 0,171404 0,171404 0,132919 0,132919 0,132919 0,16071 0,16071 0,16071
pancreas 0,068124 0,068124 0,068124 0,040648 0,040648 0,040648 nc nc nc
lung,trachea 0,127766 0,127766 0,127766 0,070585 0,070585 0,070585 0,092231 0,092231 0,092231
melanoma of the skin nc 0,817115 0,817115 0,79855 0,79855 nc nc 0,8102 nc
breast nc 0,646845 0,646845 0,07164 0,07164 nc nc 0,639846 nc
cervix nc 0,676449 0,676449 0,537809 0,537809 0,537809 0,579477 0,579477 0,579471
corpus uteri nc 0,849872 0,84987 nc 0,788961 nc nc 0,855863 nc
ovary 0,384932 0,384932 0,384932 0,278425 0,278425 0,278425 0,391911 0,391911 0,391911
prostate nc nc nc nc nc nc nc nc nc
testis nc 0,976682 0,000107 0,944376 0,944376 0,944374 nc nc nc
kidney 0,502796 0,502796 0,502798 0,383038 0,383038 0,38304 -27 0 nc
bladder 0,702463 0,702463 0,702463 0,617175 0,617175 0,617175 0,512393 0,512393 0,512536
CNS 0,70513 0,70513 0,70513 0,633853 0,633853 0,633853 0,579164 0,579164 0,579166
thyroidea nc 0,933386 0,933386 nc 0,927641 nc nc nc nc
Hodgkin lymphoma nc 0 0,000001 nc 0,000001 nc -111,3 0,265558 0,006219
non-Hodgkin lymphoma nc 0,418254 0,418266 -0,107 0 nc nc nc nc
leukaemia 0,533963 0,533963 0,533963 0,40733 0,40733 0,40733 0,461 0,499753 0,499755
nc=not converged  
b) Median survival of the uncured 
Weibull Lognormal Gamma
identity logit log-log identity logit log-log identity logit log-log
mouth,pharynx 3,053644 3,053644 3,053644 3,63118 3,63118 3,631155 6,737938 6,737938 nc
oesophagus 0,665003 0,665003 0,665003 0,612028 0,612028 0,612028 0,636204 0,636204 0,636204
stomach 0,643296 0,643296 0,643296 0,615886 0,615886 0,615886 0,617498 0,617498 0,617498
colon 1,363927 1,363927 1,363927 1,945712 1,945712 1,945696 1,364072 1,364072 1,364072
rectum 2,115203 2,115203 2,115203 2,77566 2,77566 2,775659 2,11252 2,11252 2,112518
liver 0,402671 0,402671 0,402671 0,35222 0,35222 0,35222 nc nc nc
gallbladder 0,735856 0,735856 0,735856 0,670455 0,670455 0,670455 0,702857 0,702857 0,702857
pancreas 0,396828 0,396828 0,396828 0,360412 0,360412 0,360412 nc nc nc
lung,trachea 0,600881 0,600881 0,600881 0,589414 0,589414 0,589414 0,585648 0,585648 0,585648
melanoma of the skin nc 2,849196 2,849196 3,14818 3,14818 nc nc 2,893647 nc
breast nc 10,738593 10,738584 63,963192 63,963192 nc nc 11,038505 nc
cervix nc 4,473705 4,473706 10,1 11,088599 11,088557 7,8 8,34162 8,341966
corpus uteri nc 1,917749 1,917782 nc 3,503657 nc nc 1,879487 nc
ovary 2,361046 2,361046 2,361046 2,974104 2,974104 2,974104 2,4 2,370179 2,370178
prostate nc nc nc nc nc nc nc nc nc
testis nc 0,780183 4381,38794 2,8 7,304973 7,305525 nc nc nc
kidney 2,666696 2,666696 2,666687 4,3 4,367831 4,367794 103,7 28,528497 nc
bladder 1,962403 1,962403 1,962403 3,3 3,305425 3,305421 6,976121 6,976121 6,969131
CNS 0,95708 0,95708 0,95708 1,473496 1,473496 1,473496 2,08846 2,08846 2,088434
thyroidea nc 1,776942 1,776947 nc 1,816073 nc nc nc nc
Hodgkin lymphoma nc 82,992044 83,014125 nc 295,437417 nc 166,5 37,989427 57,97409
non-Hodgkin lymphoma nc 5,090391 5,090137 43,1 30,149195 nc nc nc nc
leukaemia 1,819377 1,819377 1,819377 3,28178 3,28178 3,281776 2,036444 2,036444 2,03643  
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The non-mixture model with various link functions 
a) Proportion cured 
Weibull Lognormal Gamma
identity logit log-log identity logit log-log identity logit log-log
mouth,pharynx 0,419156 0,41915609 0,41916 0,336525 0,33652 0,336521 0,115838 0,115676 0,115526
oesophagus 0,111516 0,11151638 0,11152 0,068935 0,068935 0,068935 0,104779 0,104779 0,104779
stomach 0,216171 0,21617082 0,21617 0,162265 0,162265 0,162265 0,188206 0,188206 0,188206
colon 0,571878 0,57187851 0,57188 0,458479 0,458481 0,458481 0,578594 0,578594 0,578594
rectum 0,599906 0,59990532 0,59990 0,500119 0,500119 0,500119 0,60696 0,60696 0,60696
liver 0,087495 0,08749471 0,08749 0,05363 0,05363 0,05363 0,06121 0,06121 0,06121
gallbladder 0,16558 0,16558037 0,16558 0,104486 0,104485 0,104485 0,165555 0,165555 0,165555
pancreas 0,057207 0,05720659 0,05721 0,025313 0,025313 0,025313 0,030765 0,030765 0,030765
lung,trachea 0,107963 0,10796274 0,10796 0,040979 0,040979 0,040979 0,078728 0,078728 0,078728
melanoma of the skin nc 0,8165351 0,81654 nc 0,797127 nc nc 0,810261 nc
breast nc 0,63540815 0,63541 0,074801 0,074673 nc 0,631099 nc
cervix nc 0,67112226 0,67112 0,524216 0,524217 0,524219 0,574386 0,57437 0,57437
corpus uteri nc 0,84931843 0,84932 nc 0,784877 nc nc 0,855974 nc
ovary 0,380157 0,38015744 0,38016 0,224222 0,224218 0,224218 0,391427 0,391427 0,391427
prostate nc 0,37416166 nc nc 0 nc nc nc nc
testis nc 0,9766802 nc 0,945533 0,945556 0,945561 nc nc nc
kidney 0,49321 0,49321332 0,49321 0,37399 0,373989 0,373992 nc nc nc
bladder 0,69889 0,69889035 0,69889 0,607561 0,607545 0,607548 0,476746 0,476753 0,476738
CNS 0,696544 0,69654406 0,69654 0,62646 0,62646 0,62646 nc 0,575499 0,575499
thyroidea nc 0,93336598 0,93337 nc 0,927492 nc nc nc nc
Hodgkin lymphoma nc nc nc nc nc nc nc 0,298249 0
non-Hodgkin lymphoma 0,384373 0,38437179 0,38437 0,033548 0,033548 0,033551 nc 0,488723 nc
leukaemia 0,529786 0,5297844 0,52978 0,3743 0,374309 0,374299 0,501292 0,501291 0,50129  
b) Median survival of the uncured 
Weibull Lognormal Gamma
identity logit log-log identity logit log-log identity logit log-log
mouth,pharynx 3,062668 3,0626679 3,0626687 3,770366 3,77046 3,770452 989,274923 996,748945 1001,897179
oesophagus 0,652184 0,65218388 0,65218387 0,637183 0,637183 0,637183 0,64208 0,64208 0,64208
stomach 0,633846 0,6338458 0,63384578 0,637384 0,637384 0,637383 0,624005 0,624005 0,624004
colon 1,359052 1,3590521 1,359052 2,206933 2,206915 2,206915 1,359323 1,359322 1,359323
rectum 2,11477 2,1147722 2,1147741 3,029498 3,029497 3,029497 2,105233 2,105233 2,105233
liver 0,39125 0,39125022 0,39125022 0,36503 0,36503 0,36503 0,363403 0,363403 0,363403
gallbladder 0,714211 0,71421057 0,71421057 0,716504 0,716505 0,716505 0,714153 0,714153 0,714153
pancreas 0,383592 0,38359179 0,38359177 0,367554 0,367554 0,367554 0,367553 0,367552 0,367553
lung,trachea 0,600688 0,60068759 0,6006875 0,631385 0,631385 0,631385 0,60081 0,600811 0,60081
melanoma of the skin nc 2,8518642 2,8518646 nc 3,188128 nc nc 2,891884 nc
breast nc 11,223048 11,223021 62,598966 62,61384 nc nc 11,413796 nc
cervix nc 4,5920168 4,5919963 12,091079 12,091002 12,090817 8,579422 8,580338 8,580319
corpus uteri nc 1,9249699 1,9249856 nc 3,659544 nc nc 1,878482 nc
ovary 2,368752 2,3687519 2,3687519 3,575946 3,576026 3,576023 2,357279 2,357277 2,357279
prostate nc 17,654233 nc nc 35,024655 nc nc nc nc
testis nc 0,77974761 4387,5564 nc 6,829952 6,827945 nc nc nc
kidney 2,724993 2,7249464 2,724942 4,529215 4,529233 4,529169 nc nc nc
bladder 1,988867 1,9888618 1,9888652 3,52667 3,527062 3,526998 39,517535 39,508521 39,517546
CNS 1,014548 1,014549 1,0145497 1,528132 1,528138 1,528138 nc 4,619422 4,619422
thyroidea nc 1.7705695   .71,770572 nc 1,822188 nc nc nc nc
Hodgkin lymphoma nc 83,114922 nc nc nc nc nc 42,961868 83,014038
non-Hodgkin lymphoma 5,87058 5.8706044   2 5,8705559 25,992784 25,99407 25,993852 nc 3,91533 nc
leukaemia 1,821683 1,8216953 1,821696 3,942703 3,942492 3,942727 2,02315 2,023161 2,023166  
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Abstract 
Background Statistical cure is reached when a group of patients has the same mortality as 
cancer-free individuals, and cure models predict the cured proportion and the median survival of 
fatal cases. Cure models have seldom been applied and tested systematically across all major 
cancer sites.  
Methods Incidence and follow-up data on 23 cancers recorded at the Cancer Registry of Norway 
1963-2007 were obtained. Mixture cure models were fitted to obtain trends and up-to-date 
estimates assuming cured and uncured groups exist.  
Results The model fitted for cancers of the mouth and pharynx, esophagus, stomach, colon, 
rectum, liver, gallbladder, pancreas, lung and trachea, ovary, kidney, bladder, central nervous 
system, non-Hodgkin lymphoma and leukemia. The proportion of cured patients increased 1963-
2002 for both sexes, with the largest changes seen for leukemia (in % units), males given first 
(46.4 and 46.7) and CNS (35.9, 42.0). Median survival time for the uncured cases increased for 
colon (0.42 years and 0.61years), and rectal cancer (0.56 years, 0.75 years), and there was a 
three- fold increase in median survival time (from 0.73 years to 1.36 years) for patients with fatal 
ovarian cancers. Cancers of bladder and CNS had the highest up-to-date proportion cured (67.4% 
and 64.0 %, respectively), pancreas and liver were amongst the worst (5.7% and 9.9%, 
respectively). 
Conclusion 
Cure models are useful when monitoring progress in cancer care, but must be applied and 
interpreted with caution. The absolute estimates of the cure proportion are speculative, 
particularly for cancer sites where cure is not medically anticipated.  
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Introduction 
Increasingly, cancer patients as a group – at least those diagnosed with treatable cancers in 
higher-resource settings – survive their initial diagnosis and remain tumor-free for longer periods 
than has been observed previous decades (1) This favorable trend in cancer care has warranted 
the development of novel statistical tools to monitor the effectiveness of early-detection 
strategies and the quality of clinical care and cancer management, including procedures to 
estimate the proportion of cured patients alongside the median survival of fatal cases using so-
called cure models (2;3) . From the offset, the inherent differences between the concepts of 
clinical versus statistical cure need to be understood. Statistical cure is applicable to observations 
examined at the group level, and is distinct from medical cure of the individual, as commonly 
determined in a clinical setting on the basis of lack of specific symptoms of the patients, 
achieved, for example, when all cancerous cells in the body have been persistently eradicated 
(4). The models, when applied to population-based cancer survival data, serve to provide 
estimates of the proportion of statistically-cured individuals, that is, a group of cancer patients 
whom, after a certain time period, are observed to have little or no excess mortality relative to 
the general population.  
Such models have been applied to aid clinical interpretation of survival trends for specific cancer 
sites in one or more population. A recent EUROCARE study presented estimates of the cured 
proportion for a limited number of cancer forms (breast, lung, prostate, colon and rectum, 
stomach and all sites combined) for a subset of European cancer patients diagnosed from 1988 to 
1999 (5). Lambert et al have reported the long-term survival trends among colorectal cancer 
patients in Finland, in terms of the proportion cured and median survival of fatal cases (6) while 
trends in the proportion of childhood cancer patients with leukemia has been studied in British 
children diagnosed between 1971 and 2000 (7). 
There has however been a paucity of work examining the systematic application of cure models 
to long-term survival and trends across the major cancer types. The objective of this study is 
therefore to perform such an analysis, providing national estimates of the cured proportion and 
median survival of fatal cases for patients with the 23 most common cancer sites diagnosed in 
Norway over the period 1963 to 2007. We aimed to illustrate both the major temporal trends in 
the two estimates as well as provide up-to-date estimates of the cured proportion and the median 
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survival of patients who eventually die. A secondary aim was to assess the general applicability 
of these models in the context of statistical and clinical cure of specific cancers. 
Material and methods  
Data sources 
National incidence and follow-up data was extracted from the population-based Cancer Registry 
of Norway. The reporting of neoplasms and certain precancerous lesions to the Cancer Registry 
of Norway has been compulsory following a directive from the Ministry of Health and Social 
Affairs in 1951, further strengthened by the Health Registry Act in 2002 that included statutory 
regulations and the requirement that relevant institutions report new cases to the Registry. A 
recent evaluation suggests that multiple source reporting and effective trace-back has meant that 
the Registry has retained a high level of overall completeness for many years (8). In terms of 
validity, the Registry’s effective use of reports from pathology laboratories, clinical records and 
death certificates has been shown to provide reasonable and comparable accuracy, with only a 
small fraction of cancer registrations obtained solely from death certificate sources (DCO) (8). A 
review of registrations 2001–5 showed that three-quarters of the main cancer sites had a DCO 
proportion of less than 1%. However, for certain sites, including pancreatic and liver cancer, the 
percentages were higher, ranging from 3 to 4%.  
 
Survival data 
Incidence data on the 23 most frequently recorded cancers for the diagnostic period 1963–2007 
were obtained together with follow-up on matching vital status from the National population 
Registry. Except for precancerous diagnoses for bladder cancer and central nervous system 
(CNS) and endocrine organs, only invasive malignant cancer diagnoses were included. Patients 
with previous cancer diagnoses were therefore included given it has been shown that exclusion 
of such patients - usually diagnosed with tumor associated with inferior prognoses - may give 
higher estimates of survival by their inclusion (9).  Beginning with a total of 642,219 registered 
diagnoses of the 23 cancers under investigation: 7142 DCO cases were excluded (1.1%) 
alongside 5350 cases diagnosed at autopsy (0.8%). We removed a further 268 cases for which a 
survival time could not be estimated as event dates were missing, and 2,113 cases (0.3%) with 
either an erroneous event date (survival time < 0) and or zero survival time (survival time = 0). 
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Following these eliminations, 627,346 cases were included in the analyses described below, 
97.7% of the number extracted prior to exclusions.  
Statistical methods 
 
Relative survival (10; 11; 12) is computed as the ratio of observed (all causes) and expected 
survival and provides a measure of excess mortality (compared to the general population) 
associated with diagnosis of the disease: 
R(t)=S(t)/S*(t), 
where R(t) is relative survival, S(t) is observed and S*(t) is expected survival. 
To provide recent estimates of long-term (1- to 15-year) survival proportions of Norwegian 
cancer patients, we used the period approach of Brenner et al (13; 14; 15; 16).  
The cure proportion is estimated using the mixture cure proportion model (17; 18; 19): 
S(t) = S*(t)(  + (1 −  )Su(t)) 
where S*(t) is the expected survival,  is the proportion cured (the cure fraction), (1 −  ) is the 
proportion ‘uncured’ (or those ’bound to die’ fatal cases) and Su(t) is the survival function for the 
uncured individuals. Su(t) was modeled with a Weibull distribution with two parameters λ and γ: 
Su(t) =exp(-λ tγ ) 
If the relative survival curve does not reach a plateau then the estimate of cure is based on 
extrapolation beyond the time range of the data and becomes sensitive to the choice of 
parametric distribution. In theory, cure occurs when time approaches infinity, but in practice the 
cure proportion is estimated where the relative survival curve is seen to plateau, usually between 
six and ten years post diagnosis. Estimation of the cure model parameters is obtained using 
maximum likelihood on the individual level data. The estimation procedure is similar to that of 
De Angelis (2) but extended to model both parameters in the Weibull distribution (4).  
Temporal trends between 1963–2002 in the proportion of cured patients, and the median survival 
of fatal cases, were estimated applying the complete approach as suggested by Brenner at al. 
(14), whereby all diagnosed cases over the period irrespective of the length of their follow-up 
were used in the estimations. The main focus here was on estimating changes in trends for 
patients diagnosed at different five-year time periods, hence period of diagnosis was modeled as 
a categorical variable with the 5-year periods as the categories.  
 86 
The changes in proportion cured and median survival of uncured cases between the first period 
(1963-1967) and the last period (1998-2002) were quantified using the absolute difference 
between the estimates of both cure proportion and median survival. 95% confidence intervals for 
these differences were constructed using the delta method. 
The most up-to-date estimates of the proportion of cured patients and the median survival of fatal 
cases were modeled using the period approach with a 3-year observation window (2005-2007) 
and a 15-year follow-up, thus accruing sufficient case numbers to ensure the estimates were 
reasonably up-to-date while retaining an acceptable degree of precision. Using this method the 
follow up was set to 15years but there were no constraints on the model concerning the time at 
which a statistical cure will have to be reached. Age at diagnosis (in categories) and sex were 
modeled as covariates. 
 
All computations were conducted using the statistical software Stata (20). The mixture cure 
proportion models (4) were fitted with the strsmix command (version 1.0.2). 
 
Results 
Model fitting 
The cure models fitted well for cancers of the mouth and pharynx, esophagus, stomach, colon, 
rectum, liver, gallbladder, pancreas, lung and trachea, ovary, kidney, bladder, CNS, non-Hodgkin 
lymphoma and leukaemia. When we compared the up-to-date estimates of long term relative 
survival and the proportion cured derived from the mixture model, both estimates were very 
similar for all 15 cancer sites where convergence was reached except for Non-Hodgkin 
lymphoma and mouth and pharynx. For those two sites the plateau was not reached within 15 
years after the cancer diagnosis (at least empirically, by means of visual inspection of the relative 
survival plots). It was not possible to fit the cure proportion for eight of the 23 selected 
neoplasms (breast, prostate, cervical, endometrial, testicular, thyroid, Hodgkin lymphoma and 
melanoma of the skin). 
Trends in the proportion cured and median survival 
The proportion of cured patients significantly increased from 1963 to 2002 for both male and 
female patients where the model provided a reasonable fit, with cancers of mouth and pharynx 
among men the only exception (Table 1: IA,IB and IIA,IIB). The temporal trends are depicted 
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graphically in Figure 1. The largest increases in the cured proportion were seen for leukemia 
(46.4 and 46.7, males and females, respectively), CNS (35.4 and 42.0), Non-Hodgkin lymphoma 
(35.4 and 27.7), bladder (28.6 and 30.3), and rectum (30.2 and 31.1), all differences given in % 
units. 
The median survival time for fatal cases has increased significantly for male patients diagnosed 
with cancers of the stomach, rectum, colon, CNS, Non-Hodgkin lymphoma and leukemia. For 
females, the median survival of fatal cases increased significantly for cancers of colon, rectum, 
ovary, CNS, Non-Hodgkin lymphoma and leukemia. 
The estimates of the proportion cured for the latest period (1998-2002) tended to be higher for 
females than males, although only for cancers of the lung and CNS were the differences 
statistically significant. Overall, the highest absolute differences in median survival of fatal cases 
between the period 1963-1967 and 1998-2002 was seen for cancers of rectum (0.56 years and 
0.75 years, males and females, respectively), leukemia (0.65 years and 0.68 years) colon (0.42 
years and 0.61 years,), CNS(0.44 years and 0.31 years) and Non-Hodgkin lymphoma (0.40 years 
and 1.23 years).   
While the proportion cured has remained unchanged for patients diagnosed with ovary cancer, 
there has been about a three-fold increase in the median survival time of fatal cases (from 0.73 
years to 1.36 years) from 1963 to 2002. The prognosis for patients with gallbladder and lung 
cancers has slightly improved in terms of a higher proportion cured. However, median survival 
of fatal cases has remained unchanged for both malignancies. (Table 1: IA,IB and IIA,IIB).  
  
Up-to-date estimates of proportion cured and median survival 
 
A summary of the estimates of proportion cured and median survival of fatal cases with follow 
up 2005-2007 is depicted graphically in Figure 2 and listed in Table 1. The highest proportion 
cured was reached by the survivors of cancers of bladder and CNS where more than two thirds 
were considered statistically cured: 67.4% [62.7% to 72.1%] and 64.0 % [59.9% to 69.2%], 
respectively (square brackets indicate 95%CI). More than half of the patients were considered 
cured following diagnoses of colon and rectal cancer, with the proportion cured being 55.1 % 
[53.0% to 57.3%] and 57.7 % [54.9% to 60.9%], respectively. The poorest survival was observed 
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for cancers of pancreas and the liver, the cured proportion being only 5.7% [4.1% -7.3%] for the 
former neoplasm.  
The median survival time of fatal cases was longer than one year for eight (mouth and pharynx, 
colon, rectum, ovary, kidney, bladder, CNS and leukemia) of the 15 sites analyzed. The longest 
median survival of fatal cases was estimated for mouth and pharynx (3.05 [2.31 to 4.04], ovary 
(2.36 [2.09 to 2.67], rectum (2.11 [1.90 to 2.36] and bladder (2.19 [1.43 -2.70]). 
 
Discussion 
 
In this study, we have systematically attempted to fit cure models to 23 cancers and were able to 
derive estimates of cure for 15, and report a general increase in the proportion of cured patients 
in Norway from 1963-1967 to 1998-2002 patients diagnosed with each of these neoplasms. Over 
half of the patients diagnosed with cancers of the colon, rectum, bladder, CNS and leukemia may 
considered (statistically) cured of their cancer, while the median survival for those who 
eventually die from cancers – including cancers of the mouth and pharynx, colon, rectum, ovary, 
kidney, bladder, CNS and leukemia – are greater than one year.  
These conclusions are derived from statistical models that are based on concepts of statistical 
cure. For a number of common cancers, the relative survival function will reach a plateau at 
some point after diagnosis, with the corresponding level an indication of the proportion of 
survivors whom, as a group, no longer exhibit any excess mortality compared to the general, 
cancer-free population (at a given age and sex) (21; 22; 23). Statistical cure refers to a population 
of patients rather than to individual patients; selected long-term survivors may still die from their 
cancer even though they were considered (as part of a group) statistically cured. A critical 
assumption on applying these mixture models is therefore that there exists a cured and an 
uncured group – comprising of fatal cases or in other words, those bound to die – defined at the 
time of diagnosis. Where the cure model reached convergence and the estimates could be 
derived, particular caution must be applied in their interpretation. The absolute estimates of the 
cured proportions are speculative, particularly for those sites where statistical cure is not clearly 
indicated, e.g. where long term relative survival fails to reach a plateau (melanoma of the skin, 
female breast cancer, and prostate cancer). 
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We did not find any major differences between the estimates regardless of the choice of model 
(mixture and non-mixture), distribution and the link function. According to the literature (4), in 
most cases it does not matter if one uses the mixture or non-mixture models when the aim was to 
estimate the cure proportion and median survival of uncured cases. Our comparison of different 
distributions and link functions confirmed this finding. 
 
 It should be noted that we did not embark on any age standardization procedure, and it is 
possible therefore that the estimates might vary more were the models fitted with several 
covariates. However, the aim of this study was to compare the proportion cured estimates across 
different cancer sites and diagnostic periods; therefore the use of models based on unadjusted 
survival estimates was justified. 
There are 15 candidate sites in our study for which patients may potentially exhibit properties 
pertaining to both statistical and clinical cure, and the underlying reasons for such changes are 
likely to be multiple. Improvement in treatment and introduction of new therapies together with 
an increase in diagnostic intensity contribute to a higher proportion of cured patients, but also to 
increases in the median survival of fatal cases. Colorectal cancers are increasingly diagnosed 
earlier than previously due to a raised awareness among the general population and improved 
multimodal treatment (24). New chemotherapy for treatment of childhood and adult-onset 
leukemia was introduced in the 1970s and has led to improved survival (25;26). However, not all 
the rises in the cured proportion may represent genuine improvements in cancer care, but may be 
artifacts related to changing registration practices as for example for bladder cancer. From early 
in the 80ies the Cancer Registry of Norway coded pre-invasive bladder lesions together with 
invasive tumors, so this change in coding rather than altered treatment is reflected in changes in 
survival rates. There has been little improvement in treatment of bladder cancer so the high 
degree of change in proportion of cured patients is more likely explained by change in coding 
practices.  
The mixture cure model did not converge when estimating the proportion cured for 8 cancers, 
namely breast, prostate, cervix, endometrium, testis, thyroid, as well as Hodgkin lymphoma and 
melanoma of the skin. For a number of these cancer forms, it is reasonable to assume that 
statistical cure could not be estimated as medical cure is not established in some of these patients 
even several decades after diagnosis (including melanoma of the skin, female breast cancer, and 
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prostate cancer). Theories concerning cures for breast cancer vary from the concept that no 
patients are cured (27;28), to the idea that the hazard to patients who have survived eight years is 
no greater than that for the general population (29).  
A selection effect may have also played a role. Testicular cancer is now one of the cancers with 
the highest proportion of survivors. However, those who survive might be on average of better 
general health than observed in the general population so that the relative survival of testicular 
cancer patients does not reach a plateau but rather continues to increase even after long-term 
follow-up. For several malignancies, such as childhood cancers, Hodgkin’s lymphoma and 
testicular cancer, long-term survivors are at risk to develop life-threatening adverse induced by 
the cancer treatment many years after initial treatment and hence relative survival of these 
patients never reaches a plateau but continues to decline (30;31;32). 
For certain sites, there is an absence of statistical cure in this study, yet clinical evidence of 
patient cure. In such circumstances, there may statistical grounds as to why there is a lack of 
convergence of the proportion cure models for certain cancer sites. It is possible that the 
underlying Weibull distribution may not be sufficiently flexible to capture the shape of the long 
term survival curves. However, it should be possible to fit the model even though the assumption 
of existence of a cured and uncured fraction is violated. Another explanation could relate to the 
use of general life tables that insufficiently represent the demographics of the patient groups. It is 
known that cervical cancers are more common among women of lower social classes. When 
computing relative survival we used life tables constructed from the data on the whole 
population which might have caused underestimation of the relative survival of these patients 
and in turn caused problems in estimation of the proportion cured. 
Overall, the estimates of proportion cure for the latest period 1998-2002 were higher for females 
compared to males. This is in agreement with a number of previously-published articles: Micheli 
et al, for instance, suggest that female sex hormone may have a role in women’s superior ability 
to cope with cancer using the EUROCARE-4 data (33). However, these findings are speculative 
and have to be confirmed in future studies. 
Most cure models have been applied to specific cancer sites. A recent study demonstrated the 
effect of year of diagnosis and stage on cancer of colon using data from three French registries 
(21). Lam and colleagues applied several variants of cure models on breast cancer data with 
focus was on the statistical properties of the models, rather than the clinical interpretation of the 
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results (34). Yu and colleagues analyzed US data on Hodgkin disease and Sposto et al compared 
cure and Cox regression models using examples based on Hodgkin and non-Hodgkin lymphoma 
as well as acute lymphocytic leukemia (35). Mixture survival models have been applied to colon 
cancer data collected in Finland 1953-1992 and Weston et al has described the long-term 
survival following diagnoses of Ewing’s sarcoma, quantifying the cure in young patients (37).  
Proportion cured models are useful when monitoring progress in cancer care; however they must 
be applied and interpreted with caution. The existence of a cured and an uncured group of 
patients is a necessary but rather strong assumption underlying the mixture model. The absolute 
estimates of the cure proportion are speculative, particularly for cancer sites where a cure is not 
clearly indicated. Our results provide neither direct relationships between the changes in patient 
care, nor any information regarding the extent that there has been improved survival at the 
individual level. However, the methods may result in a better quantification of the lives of cancer 
patients beyond their initial diagnosis and aid understanding as to the reasons for increasing 
survival for certain cancers, among them improvements in therapy and management and better 
palliative care. 
 
Conflict of interest statement 
None declared. 
 92 
 
3 References 
1. Janssen-Heijnen M, Houterman S, Lemmens V, Brenner H, Steyerberg E. Prognosis for long-term 
survivors of cancer. Ann Oncol , 2007;18:1408-1413. 
2. de Angelis R, Copocaccia R, Hakulinen T, & Soderman B. Mixture models for cancer survival analysis: 
Application to population-based data with covariates. Statistics in Medicine , 1999;18:441-454. 
3. Verdecchia A, de Angelis R, Capocaccia R. Estimation and projection of cancer prevalence from 
cancer registry data. Statistics in Medicine ,2002; 21:3511-3526. 
4. Lambert P. Modeling of the cure fraction in survival studies. The Stata Journal , 2007;7:1:25. 
5. Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C. the EUROCARE 
Working Group. The cure of cancer: A European perspective. European Journal of Cancer , 
2009;45:1067-1079. 
6. Lambert P, Dickman P, Osterlund P, Andersson T, Sankila R, Glimelius B. Temporal trends in the 
proportion cured for cancer of the colon and rectum: a population-based study using data from the 
Finish Cancer Registry. Int J Cancer , 2007;121:2052-2059. 
7. Shah A, Stiller CA, Kenward MG, Vincent T, Eden T, Coleman M. Childhood leukeamia: long-term 
excess mortality and the proportion 'cured'. British Journal of Cancer , 2008;99:219-223. 
8. Larsen I, Småstuen M, Johannesen T, Langmark F, Parkin D,  Bray F. Data Quality at the Cancer 
Registry of Norway: an overview of comparability, completeness,validity and timeliness.  Eur J 
Cancer,2009; 45:7:1218-1231. 
9. Brenner H, Hakulinen T. Patients with previous cancer should not be excluded in interntional 
comperative cancer survival studies. Int. J. Cancer, 2007;121:2274-8. 
10. Ederer F, Axtell L, Cutler S. The relative survival rate: a statistical methodology. Natl Cancer 
InstMonogr , 1961;6:101-121. 
11. Dickman P, Coviello E, Hills M.  Estimating and modeling relative survival. The Stata journal, (in 
press). 
12. Dickman P, Sloggett A, Hills M, Hakulinen T . Regression models for relative survival. StatMed ,2004: 
23:51-64. 
13. Brenner H, Hakulienen T . Advanced detection of time trends in long-term cancer patient survival: 
Experience from 50 years of cancer registration in Finland. Am J Epidemiol , 2002;156:566-577. 
 93 
14. Brenner H, Gefeller O, Hakulinen T (2004). Period analysis for "up-to-date" cancer survival, data 
theory, empirical evaluation, computational realisation and applications. European Journal of Cancer 
, 2004;40:3:326-335. 
15. Brenner H, Hakulinen T. Up-to-date long-term survival estimates of patients with cancer by period 
analysis. J Clin Oncol , 2002;20:826-832. 
16. Brenner H,  Hakulinen T. Very-long-term survival rates of patients with cancer. J Clin Oncol , 
2002;20:4405-4409. 
17. Lambert P, Thomson J, Weston C, Dickman P. Estimating and modeling the cure fraction in 
population-based cancer survival analysis. Biostatistics , 2007;8: 576-594. 
18. Binbing Y, Tiwari R, Cronin K, Feuer E. Cure fraction estimation from the mixture cure models for 
grouped survival data. Statistics in medicine , 2004;23:1733-1747. 
19. Phillips N, Coldman A, McBride M. Estimating cancer prevalence using mixture models for cancer 
survival. Statistics in Medicine ,2002; 21:1257-1270. 
20. Stata Statistical Software: Release 10.2007; TX:StataCorp LP. 
21. Bejan-Angoulvant T, Bouvier A, Bossard N, Belot A, Jooste V, Lanoy G. Hazard regression model and 
cure rate model in colon cancer relative survival trends: are they telling the same story? European 
Journal of Epidemiology , 2008;23:4:251-259. 
22. Berrino F, de Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coeberg J. Survival for eight major 
cancers and all cancers combined for European adults diagnosed 1995-99: results of the EUROCARE-
4 study. Lancet Oncol , 2007;8:773-783. 
23. Black R, Bashir S. Interpretation of population-based cancer survival data. IARC Sci Publ , 1998; 
145:13-17. 
24. Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B. Colorectal cancer. Lancet. 
2010;375:1030-47. 
25. O'Leary M, Krailo M, Anderson J, Reaman G. Progress in Childhood Cancer: 50 Years of Research 
Collaboration, a Report From the Children's Oncology Group. Seminars in Oncology.2008;35 (5:484-
493). 
26. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-ManeroG.Therapeutic Advances in 
Leukemia and Myelodysplastic Syndrome Over Past 40 Years. Cancer.2008;113:7 :1933-52. 
27. Mueller C, Jeffries W . Cancer of the breast: Its outcomes as measured by the rate of dying and 
causes of death. Ann Surg , 1975;182:334-341. 
28. Brenner H,  Hakulinen T. Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever 
Cured? Journal of Clinical Oncology , 2004;22:3:432-438. 
 94 
29. McBride C, Brown B, Thompson J, Westbrook K, Milne C . Can Patients with Breast Cancer be Cured 
of Their Disease? Cancer , 1983;51:938-945. 
 
30. Oeffinger K, Nathan P,  Kremer L. Chalanges After Curative Treatment for CHildhood Cancer and 
Long-Term Follow up of Survivors. Hematol Oncol Clin N Am. 2010;24:129-149. 
31. Kiserud C, Loge J,Fosså A, Cvancarova M, Fosså S (2010). Mortality is persistently increased in 
Hodgkin's lymphoma survivors. Eur J Cancer. 2010;46 :9:1632-9. 
32. Fosså S, Gilbert E, Dores G, Chen J, McGlynn K, Schonfeld S.  Noncancer causes of death in survivors 
of testicular cancer.J Natl Cancer Inst. 2007; 99 (7:533-44). 
33. Micheli A, Ciapichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I. EUROCARE Working 
Group: The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur Journal of 
Cancer. 2009;45:1017-1027. 
34. Lam K, Fong D,  Tang O. Estimating the proportion of cured patients in a censored sample. Statistics 
in Medicine , 2005;24:1865-1879. 
35. Sposto R. Cure model analysis in cancer: an application to data from the Children's Cancer Group. 
Statistics in Medicine , 2002;21:293-312. 
36. Lambert PC, Dickman PW, Osterlund P, Andersson T, Sankila R, Glimelius B. Temporal trends in the 
proportion cured for cancer of the colon and rectum: A population-based study using data from the 
Finish cancer registry. Int Journal of Cancer ,2007; 121:2052-2059. 
37. Weston C, Douglas C, Craft A, Lewis I, Machin D. Establishing long-term survival and cure in young 
patients with Ewing's sarcoma. British Journal of Cancer ,2004; 91:225-232. 
 
 
 
 
 
 
 
 
 
 
 
 95 
Table 2:  Up-to-date estimates of proportion cured and median survival for those uncured 
                (based on patients with follow-up time 2005-2007) 
 
Cancer site No of 
patients 
Proportion 
cured  
95% CI Median of 
fatal cases 
95%CI 
      
Mouth. pharynx 2627 39.1  31.9 to 46.4 3.05 2.31 to 4.04 
Oesophagus 942 11.2  7.9 to 14.6 0.66 0.58 to 0.76 
Stomach 2660 21.4 18.4 to 24.4 0.64 0.57 to 0.73 
Colon 10938 55.1 53.0 to 57.3 1.33 1.22 to 1.46 
Rectum 5873 57.7 54.9 to 60.5 2.11 1.90 to 2.36 
Liver 562 9.9 5.4 to 14.3 0.40 0.30 to 0.53 
Gallbladder 645 16.2 11.0 to 21.3 0.74 0.60 to 0.90 
Pancreas 2913 5.7 4.1 to 7.3 0.40 0.36 to 0.44 
Lung. trachea 11395 11.7 10.6 to 12.9 0.60 0.57 to 0.63 
Ovary 2153 35.0 31.4 to 38.6 2.36 2.09 to 2.67 
Kidney 2705 46.6 37.6 to 55.7 2.67 1.64 to 4.34 
Bladder 6021 67.4 62.7 to 72.1 2.19 1.43 to 2.70 
CNS 4663 64.0 58.9 to 69.2 1.96 1.77 to 2.18 
Non-Hodgkin lymphoma 3829 39.7 28.9 to 50.5 5.09 4.58 to 5.60 
Leukaemia 2520 51.1 45.8 to 56.3 1.82 1.32 to 2.51 
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Table 1:  Trends in proportion cured and median survival of fatal cases 
I: Males 
A) proportion cured 
 1963-1967 1998-2002  
Cancer site Proportion 
cured 
95%CI Proportion 
cured 
95%CI Difference 
(% units) 
95%CI 
Mouth and 
pharynx 
60.6 55.4 to 65.8 52.7 48.7 to 56.7 -7.9 -1.4 to -1.3 
Oesophagus 4.7 1.8 to 7.6 8.2 5.5 to 10.9 3.5 -0.5 to 7.5 
Stomach 11.6 10.3 to 12.8 19.2 16.6 to 21.7 7.6  4.8 to 10.4 
Colon 31.3 27.9 to 34.6 51.7 49.1 to 54.3 20.4 16.2 to 24.6 
Rectum 22.5 18.5 to 26.5 52.7 49.4 to 55.9 30.2 25.1 to 35.3 
Liver 4.6 0.6 to 8.7 6.6 3.2 to 9.9 2.0 -3.3 to 7.3 
Gallbladder 2.1 0.0 to 5.7 16.7 10.6 to 22.7 14.6 7.6 to 21.6 
Pancreas 2.5 1.3 to 3.7 3.4 2.2 to 4.7 0.9 -0.9 to 2.7 
Lung, trachea 7.6 6.2 to 8.9 9.5 8.6 to 10.4 1.9 0.3 to 3.5 
Kidney 26.4 21.5 to 31.4 52.4 48.5 to 56.4 26.0 19.6 to 32.4 
Bladder 44.8 40.1 to 49.5 73.4 70.5 to 76.2 28.6 23.1 to 34.1 
CNS 16.2 13.1 to 19.3 52.1 29.4 to 54.8 35.9 31.8 to 40.0 
Non-Hodgkin 
lymphoma 
19.6 15.1 to 24.1 55.0 51.0 to 59.0 35.4 29.4 to 41.4 
Leukaemia 2.5 0.5 to 4.5 48.9 42.2 to 55.6 46.4 39.3 to 53.4 
 
B) median survival time of fatal cases 
 1963-1967 1998-2002  
Cancer site Median time 
(years) 
95%CI Median time 
(years) 
95%CI Difference 
(% units) 
95%CI 
Mouth and 
pharynx 
1.34 1.10 to 1.64 1.52 1.32 to 1.75 0.18 -0.06 to 0.42 
Oesophagus 0.47 0.41 to 0.53 0.56 0.50 to 0.63 0.09 -0.09 to 0.27 
Stomach 0.45 0.43 to 0.48 0.63 0.57 to 0.69 0.18 0.07 to 0.29 
Colon 0.66 0.57 to 0.75 1.08 0.96 to 1.22 0.42 0.23 to 0.61 
Rectum 1.04 0.91 to 1.20 1.60 1.41 to 1.83 0.56 0.38 to 0.74 
Liver 0.12 0.09 to 0.15 0.31 0.26 to 0.38 0.19 -0.15 to 0.53 
Gallbladder 0.35 0.25 to 0.49 0.46 0.36 to 0.61 0.11 -0.31 to 0.53 
Pancreas 0.24 0.22 to 0.27 0.32 0.30 to 0.35 0.08 -0.03 to 0.19 
Lung, trachea 0.43 0.40 to 0.46 0.47 0.45 to 0.49 0.04 -0.04 to 0.12 
Kidney 0.90 0.75 to 1.09 0.93 0.77 to 1.12 0.03 -0.23 to 0.29 
Bladder 1.55 1.29 to 1.85 1.66 1.38 to 1.99 0.11 -0.15 to 0.37 
CNS 0.44 0.38 to 0.51 0.88 0.80 to 0.97 0.44 0.26 to 0.61 
Non-Hodgkin 
lymphoma 
0.83 0.69 to 1.00 1.23 1.00 to 1.49 0.40 0.12 to 0.68 
Leukaemia 0.62 0.53 to 0.72 1.27 0.88 to 1.83 0.65 0.25 to 1.05 
 
 
 
 
 97 
II: Females 
A)  proportion cured 
 1963-1967 1998-2002  
Cancer site Proportion 
cured 
95%CI Proportion 
cured 
95%CI Difference 
(% units) 
95%CI 
Mouth and 
pharynx 
37.2 27.8 to 46.7 57.7 52.1 to 63.4 20.5 9.4 to 31.6 
Oesophagus 8.7 2.9 to 14.5 9.5 4.7 to 14.3 0.8 -6.7 to 8.3 
Stomach 10.8 9.3 to 12.4 23.4 20.4 to 27.3 12.6 8.4 to 16.8 
Colon 33.7 30.8 to 36.5 55.1 52.9 to 57.4 21.4 17.8 to 25.0 
Rectum 27.3 23.1 to 31.4 58.4 54.6 to 62.2 31.1 25.5 to 36.7 
Liver 5.6 0.0 to 11.9 10.3 5.3 to 15.3 4.7 -3.3 to 12.7 
Gallbladder 5.7 2.4 to 9.0 13.1 8.3 to 17.8 7.4 1.7 to 13.1 
Pancreas 2.1 0.7 to 3.4 4.0 2.7 to 5.4 1.9 0.0 to 3.8 
Lung, trachea 9.6 6.4 to 12.9 13.4 12.1 to 14.7 3.8 0.2 to 7.3 
Ovary 29.5 26.7 to 32.2 33.8 29.5 to 38.1 4.3 0.8 to 9.4 
Kidney 31.5  24.6 to 38.3 55.5 50.8 to 60.1 24.0 15.8 to 32.2 
Bladder 38.6 33.3 to 43.9 68.9 65.2 to 72.5 30.3 23.9 to 36.7 
CNS 29.3 25.3 to 33.3 71.3 69.1 to 73.6 42.0 37.4 to 46.6 
Non_Hodgkin 
lymphoma 
27.7 22.5 to 32.8 55.4 48.5 to 62.2 27.7 19.2 to 36.2 
Leukaemia 4.3 1.9 to 6.6 51.0 44.1 to 57.9 46.7 39.4 to 54.0 
 
B) median time of fatal cases 
 1963-1967 1998-2002  
Cancer site Median time 
(years) 
95%CI Median time 
(years) 
95%CI Difference 
(% units) 
95%CI 
Mouth and 
pharynx 
1.18 0.85 to 1.63 1.61 1.31 to 1.98 0.43 -1.25 to 2.11 
Oesophagus 0.54 0.43 to 0.68 0.63 0.53 to 0.75 0.09 -0.19 to 0.37 
Stomach 0.46 0.43 to 0.49 0.59 0.52 to 0.66 0.13 0.0 to 0.27 
Colon 0.66 0.59 to 0.74 1.27 1.15 to 1.40 0.61 0.46 to 0.76 
Rectum 1.14 0.98 to 1.31 1.89 1.59 to 2.24 0.75 0.52 to 0.98 
Liver 0.21 0.14 to 0.33 0.35 0.27 to 0.45 0.14 -0.34 to 0.62 
Gallbladder 0.23 0.19 to 0.28 0.48 0.39 to 0.59 0.25 -0.03 to 0.53 
Pancreas 0.27 0.24 to 0.30 0.35 0.31 to 0.37 0.08 -0.09 to 0.25 
Lung, trachea 0.46 0.40 to 0.53 0.53 0.50 to 0.56 0.07 -0.08 to 0.22 
Ovary 0.73 0.66 to 0.81 2.09 1.82 to 2.41 1.36 1.19 to 1.53 
Kidney 0.94 0.69 to 1.27 0.80 0.64 to 0.99 -0.14 -0.52 to 0.24 
Bladder 0.76 0.63 to 0.92 0.88 0.72 to 1.08 0.12 -0.15 to 0.39 
CNS 0.41 0.34 to 0.49 0.72 0.63 to 0.82 0.31 0.08 to 0.54 
Non-Hodgkin 
lymphoma 
0.74 0.60 to 0.89 1.97 1.38 to 2.81 1.23 0.82 to 1.64 
Leukaemia 0.59 0.50 to 0.70 1.27 0.87 to 1.84 0.68 0.27 to 1.09 
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Figure 1: Up-to-date estimates of proportion cured and median survival of fatal cases (all  
patients combined)  
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Figure 2: The estimated proportion cured and median survival time for fatal cases for 
patients diagnosed 1965-2005 
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ABSTRACT  
Background: Despite fertility-preserving initiatives, we expect post-cancer reproduction rates to 
be lower than general population rates.  
Methods: Using data from the Cancer Registry and the Medical Birth Registry of Norway, we 
analyzed post-cancer reproduction rates for the most frequent cancer types in 11,451 male and 
16,105 female survivors, compared to five matched controls from the general population. All 
were born after 1950, diagnosed from 1967-2004 at age 16-45, and with observation time from 
date of diagnosis (assigned date for controls), until pregnancy, death, age 46, or December 31, 
2006. Cox regression models were used to estimate reproduction rates, adjusted for educational 
level, parity, and diagnostic period. 
 Results: Overall, cancer survivors had lower reproduction rates than the controls, but higher 
among males than females (HR=0.74 [95% confidence interval (CI) 0.71–0.78] and HR=0.61 
[95% CI 0.58–0.64], respectively). However, malignant melanoma and thyroid cancer survivors 
did not differ from the controls, whereas the lowest hazard rates for pregnancies after cancer 
were seen after acute leukemia, cervical, and breast cancer. Increased reproduction rates during 
the study period were detected for ovarian cancer (HR=0.2 [95% CI 0.1–0.3] to HR=0.7 [95% CI 
0.5–0.9]), testicular cancer (HR=0.6 [95% CI 0.4–0.9] to HR=0.8 [95% CI 0.7–0.8]) and 
Hodgkin lymphoma diagnosed in men (HR=0.7 [95% CI 0.5–0.9] to HR=0.9 [95% CI 0.7–1.0]).  
Conclusions: Compared to controls, post-diagnostic reproduction rates were reduced in cancer 
survivors, but higher in males than females. Fertility-preserving attempts have succeeded in 
patients with ovarian and testicular cancer and males with Hodgkin lymphoma.  
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Reproduction after adult cancer: A population-based matched cohort study 
 
With improvement in prognosis and longevity after cancer, fertility and parenthood are 
important quality-of-life issues for cancer survivors and several fertility-preserving initiatives 
have been launched (1-4). Examples are introduction of gonadal preserving treatment (5), as for 
Hodgkin lymphoma (6-9) and testicular and gynecological cancers of low stage (5;10;11). 
Gonadal shielding during radiotherapy, cryopreservation of embryos and sperm cells has further 
enabled post-cancer reproduction. However, more intensive chemotherapeutic treatment has 
been initiated for other malignancies, such as breast cancer and acute leukemia, with possibly 
negative influences on post-cancer fertility. 
Most studies on reproduction after adult onset cancer are monocentric, uncontrolled, or 
limited to one cancer type (12-17). Surveys have revealed that the majority of young adults are 
both desiring to have children after cancer, and are concerned about the treatment-related 
complications (1;9;18-20). Among the few population-based studies that are performed (21;22), 
a Finnish study reported a 50% lower probability of parenting a first child after cancer for 
nulliparous individuals compared to sibling controls, but only slightly lower probabilities of 
parenting a second child (22). A Norwegian study, including childhood and adulthood cancer 
survivors, found an approximately 25% reduction in first-time birth rates among cancer survivors 
compared to the general population, without stratification for treatment (21).  
In the present nationwide study we explored gender-specific reproduction rates after adult 
onset cancer for all cancer types combined and separately for the most frequent cancer types. We 
hypothesized that the probability of post-cancer parenthood, compared to the general population, 
165 
 
would be lower for the cancer patients, but higher in male than in female survivors. We expected 
to find differences in post-cancer reproduction rates related to prediagnostic parity, initial extent 
of disease, as well as altered treatment strategies during the last four decades (12).  
 
Methods 
Data sources 
The Cancer Registry of Norway (CRN) has information on all cancer cases diagnosed 
in Norway from 1953 onwards, as all doctors are required by law to report these diagnoses. 
Mandatory reporting ensures a high level of completeness (23). Cancer type, date of diagnosis, 
extent or stage of disease at diagnosis, and initial treatment in broad terms are recorded.  Not 
included were type of chemotherapy, radiotherapy doses or target field, nor date of recurrence or 
relapse treatment. Within the CRN, the extent of disease of solid tumors is classified as localized, 
regional spread, distant spread, or unknown. Tumors of the uterine cervix are staged I-IV, 
according to FIGO (Fédération Internationale de Gynécologie et d’Obstétrique(24)).  Breast 
tumor stage I-IV refers to localized tumors (I), regional lymph node metastases (II), direct tumor 
extension to the chest wall or skin (III), or distant metastases (IV), respectively. Brain tumors, 
meaning all benign and malignant intracerebral tumors, both benign and malignant, and non-
solid tumors are not classified by stage or extent (25;26).  
The Medical Birth Registry of Norway (MBRN) was established in 1967, and collects 
data on pregnancies lasting a minimum of 16 weeks (and from 1999 all gestations with a 
duration of 12 weeks or longer), which are compulsorily reported by all doctors and midwives. 
The MBRN provides demographic data of the parents, and information on the pregnancy, like 
date of the last menstruation and gestational duration and whether the pregnancy was initiated by 
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assisted reproductive technology (ART). Date of birth or pregnancy termination is registered, 
together with measurements of the newborn like weight, length, and vital status. (27;28). 
Adoptions are not registered. 
Statistics Norway contains individual level information on all citizens, and provided 
information on educational level at the time of diagnosis, vital status as to December 31, 2006, 
and the corresponding date for emigration or death (29). 
 
Patient Selection and File Construction  
With approval from the National Data Inspectorate and the Regional Committee for 
Medical Research Ethics, data from the three above sources were linked by means of the 
personal identification number given to all Norwegian inhabitants since 1964.  
From the CRN, all cancer patients registered with their first verified malignancy in the 
age group 16 to 45 years were selected. To obtain the complete reproductive history in each 
individual, we restricted our study to cancer patients who were 16 years or younger in 1967, 
when the MBRN was established. Accordingly, only those diagnosed in the period from 1967 to 
2004 were included. . All malignant neoplasms according to the International Classification of 
Disease version 7 (ICD-7; 140-207) were included, except basal cell carcinomas. In total, 27,556 
cancer patients were finally eligible for analyses (Figure 1).  
The most common cancer types among young adult females in Norway are malignant 
melanoma, brain tumors, lymphomas, leukemia, breast, cervical, ovarian, and thyroid cancer 
(25;26). For young adult males, testicular cancer, malignant melanoma, lymphomas, leukemia 
and brain tumors, are the most frequent malignancies (25). For the tumor-specific analyses of 
these cancers, some restrictions were made regarding stage. Only stage I patients were 
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considered for analyses of cervical and ovarian cancer, since the treatment of stage II-IV patients 
in general means hysterectomy which results in post-treatment infertility, with exception of germ 
cell ovarian cancer, for which all locoregional tumors were included. Analyses of ovarian cancer 
tumors were restricted to invasive only (borderline tumors excluded). Because of prognostic and 
therapeutic differences, subanalyses of the effect of ovarian cancer were stratified according to 
epithelial stage I and germ cell or sex-cord tumors. 
To circumvent the lack of treatment information at an individual level, reproduction rates 
were analyzed according to the general treatment guidelines throughout the periods studied. A 
table covering the main changes during the study period was developed, to allow for a 
stratification of the different treatment-related periods (Table 1). The impact of different 
treatment modalities on fertility are published elsewhere (2;4;30). 
A comparison group from the general population, for simplicity also called the controls, 
consisted of five age- and-gender-matched individuals per patient, selected from the Office of the 
National Registrar. Like for the cancer survivor cohort, information on pregnancy history (for 
both genders) was provided from the MBRN, and educational status and dates of death or 
emigration from SSB. All controls had to be alive and living in Norway at the time of diagnosis 
of the matched patient, and none of the controls had been diagnosed with cancer before the time 
of being matched. For the comparison group, an assigned “date of diagnosis” was defined using 
the date of diagnosis for the matched patient. Likewise, the expressions “post-cancer pregnancy” 
and “post-cancer parenthood” were used both for male and female cancer survivors and controls. 
As a measure of the ability to conceive after cancer, the main outcome was the first post-
cancer pregnancy, independent of duration and outcome, including registered stillbirths and 
abortions. We defined pregnancies after cancer as gestations with the last menstruation dating 
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coincidently with or later than the date of diagnosis, using the date of birth as the event point in 
time. When the date of last menstruation was missing (N=4,666 (7.1%)), the time span between 
the date of diagnosis and the date of birth together with the pregnancy duration were used to 
categorize the pregnancy as initiated before or after the cancer diagnosis. Educational level was 
included as a proxy of socio-economic status, categorized based on total duration, low (≤9 
years), medium (10-14 years), high (≥15 years) or unknown.   
 
Statistical analyses 
Data were described with median and range for continuous data and counts and 
proportions for categorical data. The observation time was defined as the interval from the actual 
or assigned date of diagnosis to the date of the first post-cancer birth, date of death or emigration, 
attained age 46 or December 31, 2006, whichever occurred first.   
Cox proportional hazards models were fitted to compute post-cancer reproduction 
hazards rates for the cancer survivors compared to the controls. Proportional hazards 
assumptions were checked by visual inspection of log-log plots. The models were fitted 
separately for each gender and for selected diagnoses, and stratified by matched sets (a survivor 
and his/her corresponding five controls). 
The hazard rates (HR) with 95% confidence intervals (95% CI) were adjusted for 
prediagnostic parity and educational level at diagnosis. In addition, subanalyses were performed 
for selected diagnoses, stratifying on diagnostic period, (Table 1), extent of disease, and 
prediagnostic parity.  
Cumulative reproduction curves were derived using a competing risk approach. For 
several of the cancer diagnoses included, the prognosis is quite poor and death as a competing 
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event was thus incorporated into the analyses. The occurrence of one type of event may influence 
or fundamentally alter the probability of occurrence of the main event, requiring consideration of 
the competing events when depicting the cumulative incidences (31). However, when computing 
the hazard ratios for post-cancer childbirth, it is still possible to fit a proportional hazards model 
and treat the competing event as censored. Resulting hazard rates convey the information about 
the mechanisms associated with the specific outcome.  
P-values <0.05 were considered statistically significant, and all the tests were two-sided. 
Descriptive statistics and Cox-analyses were performed using SPSS and competing risk analyses 
using Stata. 
 
Results 
Among the 11,451 male cancer survivors, 23% initiated at least one pregnancy after 
cancer, compared to 32% among the males in the age-matched comparison group (p<0.001, 
Table 2). For female cancer survivors (N=16,105), 13% achieved a post-cancer pregnancy, in 
comparison with 22% among the controls (p<0.001). Median age at diagnosis for all cancer types 
combined was 36 years for females and 32 years for males, and median observation time 6.2 and 
6.5 years, respectively. When the father was a cancer survivor, 6% of the first post-cancer 
pregnancies were initiated by ART (male comparison group 2%, p<0.001). However, the 
proportions of female patients and controls using ART were about the same (2%). In total, 7,670 
post-cancer pregnancies were registered, resulting in 7,594 liveborn children among the cancer 
survivors (Table 2).  
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The largest proportions of individuals with at least one post-cancer pregnancy were found 
in both genders with thyroid cancer, Hodgkin lymphoma or malignant melanoma, and for the 
gender-specific malignancies testicular and ovarian germ cell or sex-cord cancer (Table 3). 
The hazard rates of post-cancer pregnancies were in general below 1 for the cancer 
survivors. Exceptions were malignant melanoma and thyroid cancer survivors, whose 
reproduction rates were similar to those of controls. Male survivors had higher hazard rate ratios 
for post-cancer parenthood than females (HR=0.74 vs. 0.61). Female survivors of leukemia, 
breast, or cervical cancer had the lowest probability of a post-cancer pregnancy with HRs lower 
than 0.4 (Table 3).  
Comparing the different treatment periods with each other, the biggest difference were 
seen for patients with epithelial ovarian cancer stage I, with HR of post-cancer pregnancies 
increasing from HR=0.06 to HR=0.61 (Table 4). For survivors of ovarian germ cell or sex-cord 
tumors the hazard rates almost doubled.  Also for males with Hodgkin lymphoma and testicular 
cancer, increasing rates were observed from the first to second period whereas for female 
Hodgkin lymphoma survivors, the rates did not change. 
Figure 2 depicts stratification by extent of disease and number of children prior to 
diagnosis. For all female survivors, the hazard rate of a post-cancer pregnancy was lower for 
patients with at least one child at diagnosis compared to those who were childless at diagnosis 
(HR=0.52 vs. HR= 0.73), whereas no similar difference was observed for overall male cancer 
patients (HR=0.74 vs. HR=0.75, for prediagnostic parity ≥1 and 0, respectively). Female 
survivors initiated pregnancies after a diagnosis of metastatic cancer only exceptionally 
(HR=0.2), whereas men had twice as high probability to parent a child even after advanced 
disease, regardless pre-diagnostic parity (Figure 2). 
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Competing risk curves depict the difference in crude cumulative reproduction between 
cancer patients and their comparison group (Figure 3). Except for males diagnosed with Hodgkin 
lymphoma the last treatment period, the plot shows continuous subfecundity for the cancer 
survivors, from the time of diagnosis and the 15 years of observation.  Even if some of the curves 
show a steeper gradient some years after diagnosis, no real catch-up effect was seen, compared 
to the curves depicting controls.  
 
Discussion 
 Reproduction rates after cancer for 27,556 patients diagnosed from 1967 to 2004 were for 
all cancer types combined lower than for the comparison group. The hazard ratios of post-cancer 
pregnancies were higher among males than among females, male cancer survivors had a 26% 
reduction and the corresponding figure was 39% among females, with a median observation time 
of more than 6 years. Exceptions were malignant melanoma and thyroid cancer where both 
genders experienced similar rates as those of controls. The hazard ratios for pregnancies among 
cancer survivors have increased during the study period for several malignancies, corresponding 
to changes in treatment, in particular for females diagnosed with ovarian cancer stage I and for 
male survivors of Hodgkin lymphoma and testicular cancer.   
Among the limitations of our study, is lack of information about partner status  at 
diagnosis, the attempts of achieving parenthood after cancer and whether ART was used due to 
the patient’s or the partner’s subfertility. For female cancer survivors without a partner at 
diagnosis, we know from other studies that they tend to stay single to a larger degree than male 
survivors (32). Not available in the registry files or only occasionally reported were detailed 
prognostic markers (like hormonal receptor status for breast cancer) and data on induced 
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abortions or early miscarriages. We are aware that there is a slight underestimation of parity for 
men as there are about 2% of children born for whom their fathers are not reported to the MBRN 
(33). On the other hand, both for the cancer survivors and the general population, there are a 
small number of males registered with fatherhood after cancer, where the child actually has a 
different biological father.  
As expected, females had lower probabilities than males to initiate a pregnancy after 
cancer. In general, females with at least one child before cancer had lower reproduction rates 
than females childless at diagnosis. This difference was not seen among males with similar 
parity. The distress related to a pregnancy and perhaps the fair of recurrence during eventually 
offspring’s childhood contributes to this observation as female cancer survivors may prevent to 
conceive if they do not feel well enough. The desire to have a(nother) child might also change 
during the process of being diagnosed and treated for a malignancy (34). Fertility-preserving 
treatment for women is currently limited compared to the situation for male patients, since men 
have been offered semen cryopreservation for more than 30 years (35). No real similar 
opportunities are offered female patients, even if cryopreservation of embryos has been offered 
for many years. It might not always be possible since it requires a partner, a hormonal 
stimulation, and results in a treatment postponement. Cryopreservation of ovarian tissue or 
oocytes has occasionally helped females to achieve post-cancer parenthood, but is still 
considered experimental. In vitro fertilization was significantly more frequently used by male 
compared to female cancer survivors, reflecting the possibility of sperm cryopreservation, even 
though the proportion of Norwegian cancer survivors using the preserved sperm is modest (9).  
Breast cancer survivors had the lowest rates of post-cancer motherhood (Table 3 and 4, 
(15;16). This might be explained by ovariotoxic treatment with ovarian ablation before 1980 
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(ovarian irradiation or oophorectomy), gradually substituted with tamoxifen for estrogen receptor 
positive (ER+) tumors during the 1980s (36;37). Since the 1990s, more intensive chemotherapy, 
also for lower stages, and prolonged endocrine therapy, has lead to a considerable risk of 
premature ovarian failure (POF), especially taken the high median age at diagnosis (39 years) 
into account (38-40)(Table 1). It is believed that modern chemotherapy (FEC) works partly 
through reversible ovarian ablation in young women with ER+ tumors, but presumably less in 
younger women (41).  It remains to prove if ovarian ablation through long-term antiestrogen 
therapy (more than 5 years) is prognostic beneficial, and thereby further may challenge the task 
of fertility-preservation after breast cancer (42). With an increasing maternal age at first 
pregnancy (26) and a prolonged endocrine treatment, it is likely that the wish to have a child 
after cancer might partly be the reason for early discontinuation of hormonal therapy in younger 
women, as recently reported (43). The above explanations for low rates of post-cancer 
parenthood are in contrast to Madanat et al’s interpretation expressing a fear of a hormonally 
driven risk of recurrence associated with a subsequent pregnancy (22). We have recently 
published a study demonstrating that women with subsequent pregnancies had no impaired 
survival, in line with similar studies, presumably caused by a selection mechanism known as “the 
healthy mother effect”(15;16;26;44). 
For low risk ovarian cancer stage I, action was taken during the 1980s to preserve fertility 
in young females with a wish to conceive (5;45;46). Our data show the success of such attempts. 
For germ cell ovarian cancer, the treatment has generally been fertility-preserving during the 
entire study period as ipsilateral oophorectomy has commonly been performed. However, some 
of these are phenotypic women but with chromosomal abnormalities and inherited infecundity 
and they will thus not benefit from fertility-preserving treatment (5;46).  
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No change in reproduction rates over time were seen for cervical cancer patients. 
Subanalyses thus demonstrated that 159 of 190 females with cervical cancer and subsequent 
pregnancies were stage IA1, for whom conization has been the standard treatment since the 
1970s if no high risk factors were present (Table 1 and S1, the second available online) (5;46). 
The prognosis for testicular cancer has improved dramatically during the period studied, 
which also is reflected in increasing rates of post-cancer parenthood over the study period. The 
decrease in the reproduction rates for patients diagnosed during the 1980s might be caused by the 
introduction of retroperitoneal lymph node dissections (RPLND) which at least in the first years, 
caused nerve damage in 90% and thereby dry ejaculation (47). During the late 1980s the 
extensive bilateral intervention were replaced by nervesparing RPLND, and surveillance for 
stage I nonseminoma testicular cancer patients (19). Among testicular patients childless at 
diagnosis a subgroup of men with inherent fertility problems would probably have lifelong 
difficulties to initiate a pregnancy, due to subfertility linked to the diagnosis (48;49). However, 
most testicular cancer survivors have a relatively low incidence of post-treatment azoospermia, 
and experience recovery of spermatogenesis during a few years (50). An overall 15-year 
reproduction rate of 71% among former testicular cancer patients attempting to achieve 
parenthood after cancer was reported from a national survey based study, which is consistent 
with our findings (19). Further, we saw a weak negative association between stage of disease and 
post-diagnostic parenthood, also described earlier (48). Overall, prediagnostic parity was not a 
predictor of subsequent fatherhood after testicular cancer, and this is in contrast to the findings of 
Cvancarova et al (12).   
     Malignant melanoma had similar reproduction rates as the control group. A localized 
malignant melanoma will in most cases only require surgical removal, and presumably does not 
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interfere with family planning in the way more invasive malignancies might do. However, the 
counseling of the female patients about future pregnancies might have varied for malignant 
melanoma in particular and for cancer in general. Doctors have for decades been concerned 
about an increased risk of cancer recurrence caused by the hormonal changes during pregnancy. 
In recent years several studies have failed in verifying such a risk (26;51;52). Compared to 
hospital-based studies, our reproduction rates for malignant melanoma in both gender are much 
higher, which underscores the selection-problem including less low stage patients materials from 
oncological units (53;54).  
 
A pregnancy after treatment for thyroid cancer is regarded safe today, and the good 
prognosis is likely to support a former cancer patient’s choice of having a family, expressed by 
the similar reproduction rates as the controls. Both for males and females receiving radioiodine 
therapy, a transient period of gonadotoxicity is reported, but with recovery within a year. Women 
might be at risk for a slightly lower age at menopause at least when treated at age 40 or older 
(55;56).  
We have included brain tumors in our study since the incidence among young adults is 
quite high, even though the group is very heterogeneous. Disturbances of the hypothalamic-
pituitary axis are common sequelae of head tumor treatment, caused by cranial surgery and in 
particular radiotherapy. Normal reproductive cycles can be recreated with administration of 
exogenous hormones (57;58). The severe prognosis of glioblastoma and other highly malignant 
cranial tumors might influence the fecundity itself.  
Regarding Hodgkin lymphoma in males, we found an improvement over time, and higher 
reproductive ability than in females with Hodgkin lymphoma (21). In accordance with our 
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results, a survey-based study by Kiserud reported that 63% of female and 75% of male Hodgkin 
lymphoma survivors succeeded among those who attempted post-cancer parenthood (9). Male 
patients more than females seem to have benefitted from the treatment change to ABVD (Table 
1), at least based on our post-treatment reproduction rates. There might, however, be other 
reasons than POF explaining the gender difference, and based on the data available, we are not 
able to measure the portion of females experiencing ovarian failure some time after treatment. 
Unlike Hodgkin lymphoma patients, those with Non-Hodgkin have not been offered less 
gonadotoxic treatment in recent years, rather more intensive treatment for some of the 
subgroups. However, with improved diagnostics and higher cure rates, fertility preservation is 
crucial. Since Non-Hodgkin’s lymphoma survivors make up a heterogeneous group with 
correspondingly different treatment regimes, the reported estimates vary widely: Pregnancy rates 
vary from 27 to 64% post-treatment and from 6 to 44% of the female patients may develop POF. 
Similarly, the estimates of males with impaired spermatogenesis vary from 17 to 100% (59-61). 
Monocentric or smaller materials might also have an age-distribution which influences the 
outcomes and make comparisons less appropriate.  
Acute leukemia is an example of a malignancy where both the severity of the disease and 
the treatment heavily influence on post-cancer reproduction, despite the low median age at 
diagnosis. The alkylating agents used or the high total dose of combined chemotherapeutic 
agents and eventually craniospinal or total body irradiation represents a serious fertility threat. 
Pretreatment options to preserve fertility, at least for women, are often limited, since the 
treatment has to be initiated immediately after diagnosis (62). Ovarian tissue cryopreservation 
might not be safe for patients with leukemia, since the graft could be contaminated with 
malignant cells and a possible risk of recurrence exists during transplantation (63). The literature 
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on post-treatment reproduction in adult leukemia patients is scarce, as most studies focus on 
fertility and parenthood after childhood acute leukemia. A Japanese survey-based study revealed 
that only 3.8% of adult long-term survivors of either gender became parents subsequently (64). 
This is a large controlled nationwide study including the reproductive history of 27,556 
adult cancer patients. We were able to use registry information covering the whole Norwegian 
population diagnosed with cancer for the relevant age groups (16-45 years) and during a period 
of almost 40 years. It could have been argued that observation only until age 46 for males was 
too short, but only 3% (27) of men are fathering children after that age in our cohort. This 
linkage also allowed us to compare different cancer types with each other. Post-diagnostic 
parenthood is for several cancer types a quite seldom event, and large numbers of patients are 
required to compute statistically trustworthy estimates. Comparing our results with other 
population-based studies, even with some differences in study design, we found in general 
similar results. However, the most recent therapeutic improvements might not be reflected in 
studies published some years ago, and treatment-related factors are seldom considered in 
registry-based cohorts (21;22). Several quite large cohorts have been reported on from hospital-
based studies, but these studies might have a selection-problem, which may in part explain why 
the estimates differ substantially (9;12;13;53). 
 
Compared to controls, post-diagnostic reproduction rates were reduced in cancer 
survivors, but higher in males than females. Fertility-preserving attempts have succeeded in 
patients with ovarian and testicular cancer and males with Hodgkin lymphoma. To further 
improve the young adult cancer patients’ chances of subsequent parenthood, multidisciplinary 
counseling to provide the best options of cancer treatment and future fertility should be offered. 
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Figure and tables 
 
Figure 1 
Cancer patients eligible for the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Born ≥1951 
Diagnosed and registered in the 
CRN with a first malignancy 
1967-2004 
Age 16-45 at diagnosis 
 
16,435 women 
11,845 men 
Excluded: 
Diagnosed after emigration 
 
20 women 
18 men 
Excluded: 
With no or unsure histological 
verification 
159 women 
163 men 
Excluded: 
Diagnosed by autopsy 
151 women 
213 men 
Eligible patients with verified 
invasive cancer 
16,105 women 
11,451 men 
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Figure 2 
Parity and extent of the disease at diagnosis. 
Forest plot depicting hazard rates for post-cancer pregnancies when stratified on prediagnostic 
parity and stage or extent of disease (when relevant). The analyses are adjusted for age and 
educational level at diagnosis. Only the stages where at least ten patients were registered with a 
pregnancy after cancer have been included. For malignant melanoma in males, 11 became 
fathers post-cancer among those with locoregional disease and childless at diagnosis, HR 1.17 
[0.42 to 3.22]. Broad confidence intervals reflect the small number of events in some groups.  
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Figure 3 
Competing risk plot. Controls depicted with solid red lines, and patients in dotted blue lines. Confidence 
intervals (95%) with thin solid lines. 
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Table 1 
Major treatment strategies during the period studied. Only primary treatment for in general non-
metastatic disease is given in the table. All years given in the table signaling changing treatment routines 
are approximately, since there might have been regional differences in implementation. Abbreviations 
are explained below. 
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Abbreviations: 
ABVD: Doxorubicin, bleomycin, vinblastine, and dacarbazine 
ALL: Acute lymphatic leukemia 
AML: Acute myelogenous leukemia 
BEP: Bleomycin, etopocid, cisplatin 
ChlVPP: Chlorambucile, vinblastine, procarbazine, prednisone 
CHOD: Cyclophosphamide, doxorubicin, vincristine, dexamethasone 
CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisone 
CMF: Cyclophosphamide, methotrexate, 5-FU 
COAP: Cyclophosphamide, vincristine, cytarabine, prednisone 
COP: Cyclophosphamide, vincristine, prednisone 
CT: Chemotherapy 
CVB: Cisplatin, vinblastine, bleomycin  
EBVP: Epirubicin, bleomycin, vinblastine, prednisone 
FEC: 5-FU, epirubicine, cyclophosphamide 
Hammersmith: Cyclophosphamide, doxorubicin, methotrexate, vincristine 
MVPP: Mustine, vinblastine, procarbazine, prednisone 
POF: Premature ovarian failure (premature menopause) 
4 RPLND: Retroperitoneal lymph node dissection 
RT: Radiotherapy 
TRAP/PRAP: Tioguanin/merkaptopurin, daunorubicin, cytarabine, prednisone 
T = tumor 
 
* Perioperative CT: Day 1 cyclophosphamide, 5-FU, vincristine, day 7 cyclophosphamide, methotrexate, 
vincristine  
†Cyclophosphamide, 5-FU, methotrexate 
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Table 2 
Cohort characteristics of all cancer patients and their age- and gender-matched controls 
 Male patients Male controls Female 
patients 
Female 
controls 
Total number 11,451 57,200 16,105 80,500 
Median age at diagnosis * 32 years  32 years  36 years  36 years  
Median observation time 6.2 years (0-
29.8) 
8.2 years (0-
29.9) 
5.0 years (0-
29.8) 
6.5 years (0-
29.8) 
Deceased   2,651 (23%) 530 (0.9%) 3,098 (19%) 266 (0.3%) 
     
Individuals with at least one post-
cancer pregnancy 
2,618 (23%) 18,292 (32%) 2,157 (13%) 17,279 (22%) 
Total number of pregnancies 
after diagnosis 
4,273 31,636 3,407 27,019 
Total number of liveborn 
children after diagnosis 
4,238 
(99.2%) 
31,488 
(99.5%) 
3,356 
(98.5%) 
26,712 
(98.9%) 
Use of ART† (total number) 263 (6%) 608 (2%) 81 (2%) 606 (2%) 
     
Educational level, low (≤9 
years)‡ 
3,244 (28%) 15,130(26%) 4,592 (29%) 21,022 (26%) 
Educational level, medium (10-
14 years) 
5,293 (46%) 24,709 (43%) 6,918 (43%) 33,286 (41%) 
Educational level, high (≥15 
years) 
2,553 (22%) 12,026 (21%) 4,134 (26%) 20,839 (26%) 
 
Footnote: 
*Range 16-45 years 
†ART= assisted reproductive technologies, including in vitro fertilization 
‡Educational level unknown not included in the table, 4%, 10%, 2% and 7%, respectively.  
 
 
 
 
 
 
 
 
 
 
 
196 
 
Table 3 
Characteristics of the study population for each of the most frequent cancer types. 
Post-diagnosis parenthood frequencies are displayed in absolute numbers and as a percentage of the 
total of pregnancy cases.  Hazard rates (HRs) in comparison to the control population. Bold=significantly 
different from the comparison group. 
 
 Total 
number 
 
 
M               F 
Median 
age 
(years)* 
 
M        
F 
Median 
obs. 
time 
(years)† 
M        
F 
Total no. of 
patients with 
post-cancer 
pregnancies (%) 
M               F 
Deceased,  
number, (%) 
 
      M                 
F 
Reproduction after 
cancer, HR [95% CI]‡ 
 
 
M                                  F 
Breast cancer  4,06
1 
 39  3.6  124   (3)  828  (20)  0.33 
 [0.27 to 0.39] 
Cervical cancer 
stage I 
 1,97
0 
 33  8.2  190 (10)  143    (7)  0.34 
 [0.29 to 0.40] 
Ovarian cancer 
stage I 
 402  32  8.7 
 
70 (17)  22    (6)  0.43  
[0.33 to 0.56] 
 - epithelial stage 
I 
 255  34  7.5  28 (11)  17    (7)  0.32  
[0.22 to 0.49] 
 - germ cell/ sex-
cord § 
 137  26  11.2  41 (30)  4    (3)  0.57 
 [0.40 to 0.81] 
Testicular cancer 3,511  29  9.8  1,081(31)  174 (5)  0.68  
[0.63 to 0.72] 
 
Malignant 
melanoma 
1,453 2,49
5 
34 32 6.5 8.2 410 (28) 716 (29) 223 
(15) 
168   (7) 1.03 
 [0.92 to 1.16] 
0.93  
[0.85 to 1.01] 
Brain tumors 1,374 1,27
4 
31 32 4.9 5.2 252 (18) 208 (16) 460 
(34) 
301 (24) 0.70 
 [0.61 to 
0.81] 
0.59  
[0.51 to 0.69] 
Thyroid cancer 241 947 32 31 10.
2 
9.2 97 (40) 315 (33) 10   (4) 6    (1) 1.11  
[0.86 to 1.44] 
0.95 [0.83 to 
1.08] 
Non-Hodgkin  
lymphoma 
729 468 34 34 5.4 4.4 109 (15) 75  16) 
230 
(32) 
118  (25) 
0.61  
[0.49 to 0.76] 
0.67 
 [0.51 to 0.88] 
Hodgkin 
lymphoma 
727 507 26 25 10.
8 
8.9 264 (36) 162  32) 84 (12) 54  (11) 0.79  
[0.69 to 0.92] 
0.61 [0.51 to 0 
.73] 
Acute leukemia 362 273 27 28 2.6 1.9 42 (12) 23   (8) 214 
(59) 
162  (59) 0.57 
 [0.40 to 
0.80] 
0.35 
 [0.22 to 0.56] 
All cancer types 
combined 
11,451 16,1
05 
32 36 6.2 5.0 2,618 
(23) 
2,164 
(13) 
2,651 
(23) 
3,098 
(19) 
0.74  
[0.71 to 0.78] 
0.61 
 [0.58 to 0.64] 
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Footnote: 
*Median age at diagnosis 
†Median observation time: From date of diagnosis until death, emigration, age 46, or date 31 Dec, 2006. 
‡HRs adjusted for the number of children prior to diagnosis and educational level at diagnosis. 
§Germ cell and sex-cord ovarian tumors; localized and locoregional stages included. 
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Table 4 
Reproduction rates for the most frequent cancer types. Hazard rates for post-cancer parenthood for the 
most frequent cancer types, separated into different periods to assess the impact of major changes in 
treatment on reproduction rates. The HRs for the matched comparison group for each cancer type is set 
to 1.0. Malignant melanomas, thyroid cancers and brain tumors are excluded since no major changes in 
treatment has occurred during the period studied. (See table 1 for major treatment changes during the 
period studied). Bold=significantly different from the comparison group. 
 
 
 Time 
periods 
Male 
patients,  
no. (%)* 
Male patients,  
HR [95% CI] 
Female 
patients,  
no. (%)* 
Female patients, 
HR [95% CI] 
Breast cancer 1967-1988   268 (12) 0.35 [0.24 to 0.51] 
1989-2000   2,563   (3) 0.35 [0.27 to 0.44] 
2001-2004   1,230   (1) 0.22 [0.13 to 0.38] 
Cervical cancer stage I 1967-1987   364 (15) 0.31 [0.23 to 0.42] 
1988-2004   1,606   (8) 0.35 [0.29 to 0.42] 
Ovarian cancer stage I 1967-1987   92 (16) 0.19 [0.11 to 0.32] 
1988-2004   310 (18) 0.67 [0.49 to 0.90] 
- epithelial stage I 1967-1987   54   (6) 0.06 [0.02 to 0.19] 
1988-2004   201 (12) 0.61 [0.39 to 0.95] 
- germ cell/ sex-cord  1967-1987   37 (32) 0.38 [0.20 to 0.71] 
1988-2004   100 (29) 0.74 [0.48 to 1.13] 
Testicular cancer 1967-1979 131 (38) 0.61 [0.43 to 0.86]   
1980-1988 662 (41) 0.51 [0.45 to 0.59]   
1989-2004 2,718 (28) 0.76 [0.70 to 0.83]   
Non-Hodgkin lymphoma 1967-1974 8 (50) 0.85 [0.09 to 8.12] 6 (33) 0.41 [0.07 to 2.55] 
1975-2004 721 (15) 0.60 [0.48 to 0.75] 462 (16) 0.67 [0.51 to 0.87] 
Hodgkin  lymphoma 1967-1987 204 (47) 0.68 [0.53 to 0.87] 131 (45) 0.68 [0.50 to 0.92] 
1988-2004 523 (32) 0.87 [0.73 to 1.04] 376 (27) 0.57 [0.46 to 0.71] 
Acute leukemia 
 
1967-1982 65   (8) 0.84 [0.27 to 2.68] 43   (9) 0.24 [0.08 to 0.74] 
1983-2004 297 (13) 0.55 [0.38 to 0.80] 230   (8) 0.37 [0.23 to 0.62] 
 
Footnote: 
*Total number diagnosed in each period and percentage of individuals with at least one post-cancer 
pregnancy. 
 

